• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Katayama Ryohei  片山 量平

… Alternative Names

RYOUHEI Katayama  片山 量平

Less
Researcher Number 60435542
Other IDs
  • ORCIDhttps://orcid.org/0000-0001-7394-895X
Affiliation (Current) 2025: 公益財団法人がん研究会, がん化学療法センター 基礎研究部, 部長
Affiliation (based on the past Project Information) *help 2017 – 2024: 公益財団法人がん研究会, がん化学療法センター 基礎研究部, 部長
2016: 公益財団法人がん研究会, がん化学療法センター 基礎研究部, 主任研究員
2015: 公益財団法人がん研究会, がん化学療法センター・基礎研究部, 研究員
2015: 公益財団法人がん研究会, その他部局等, 主任研究員
2014: 公益財団法人がん研究会, その他部局等, 研究員 … More
2013: 公益財団法人がん研究会, がん化学療法センター 基礎研究部, 研究員
2009: 財団法人癌研究会, 癌化学療法センター基礎研究部, 研究員
2007 – 2009: Japanese Foundation For Cancer Research, 癌化学療法センター・基礎研究部, 研究員
2008: Japanese Foundation For Cancer Research, 癌化学療法センター・基礎研究部, 研究員
2008: 癌化学療法センター, 基礎研究部, 研究員
2007: (財)癌研究会, 癌化学療法センター基礎研究部, 研究員 Less
Review Section/Research Field
Principal Investigator
Tumor therapeutics / Medium-sized Section 50:Oncology and related fields / Basic Section 50020:Tumor diagnostics and therapeutics-related / Pathological medical chemistry
Except Principal Investigator
Medium-sized Section 53:Organ-based internal medicine and related fields / Medium-sized Section 90:Biomedical engineering and related fields / Basic Section 50010:Tumor biology-related / Complex systems / Tumor diagnostics / Tumor biology / Biological Sciences
Keywords
Principal Investigator
分子標的薬 / 肺がん / 薬剤耐性 / がん / キナーゼ / 過剰活性化 / ROS1 / EGFR / 耐性 / 遺伝子変異 … More / 耐性機構 / ALK / チロシンキナーゼ阻害薬 / 獲得耐性 / ABCトランスポーター / 分子動力学シミュレーション / がん免疫療法 / ドライバーがん遺伝子 / 残存腫瘍 / 治療残存細胞 / ERBB2 / 耐性克服療法 / 融合遺伝子 / チロシンキナーゼ阻害薬(TKI) / 耐性克服法 / Driver Oncogene / Driver oncogene / 細胞死 / チロシンキナーゼ / 相互排他性 / がん遺伝子 / 肺腺がん / 分子標的治療 / 分子標的治療薬 / RET / ROS / 変異 / 多剤耐性 / Side Population / 抗がん剤耐性 / がん幹細胞 … More
Except Principal Investigator
癌幹細胞 / 大腸癌 / 癌 / 腫瘍微小環境 / 2型肺胞上皮細胞 / Oct4 / 肺癌 / 2型肺胞上皮細胞 / EGFR変異 / 非小細胞肺癌 / Oct4 / 非小細胞癌 / 個別化医療 / 硬さ / がん / 薬物感受性 / 組織工学 / 遺伝子発現 / 生物学的因子 / 物理化学的因子 / 三次元培養 / がん細胞 / 遺伝子変異 / 化学療法 / プロテオゲノムプロファイリング / 薬効評価 / 大腸癌細胞株 / 薬剤感受性 / 癌細胞株 / 再生医療 / 数理モデル / 臨床 / 数理科学 / 計算機科学 / 遺伝子 / 細胞・組織 / プロテオミクス解析 / 肺がん / 大腸がん / 薬剤耐性機序 / リン酸化プロテオーム解析 / シゲナル伝達 / 薬学 / 医療・福祉 / ゲノム / シグナル伝達 Less
  • Research Projects

    (15 results)
  • Research Products

    (225 results)
  • Co-Researchers

    (43 People)
  •  Analysis of cell survival signals and tumor microenvironment in the drug-tolerant persister cellsPrincipal Investigator

    • Principal Investigator
      片山 量平
    • Project Period (FY)
      2024 – 2026
    • Research Category
      Grant-in-Aid for Scientific Research (B)
    • Review Section
      Basic Section 50020:Tumor diagnostics and therapeutics-related
    • Research Institution
      Japanese Foundation for Cancer Research
  •  Establishment of a mouse model of Oct4-positive lung cancer stem cells and development of innovative therapies to eradicate cancer stem cells

    • Principal Investigator
      Ohashi Kadoaki
    • Project Period (FY)
      2022 – 2023
    • Research Category
      Grant-in-Aid for Challenging Research (Exploratory)
    • Review Section
      Medium-sized Section 53:Organ-based internal medicine and related fields
    • Research Institution
      Okayama University
  •  Searching druggable target sites by developing refined molecular dynamic simulationsPrincipal Investigator

    • Principal Investigator
      片山 量平
    • Project Period (FY)
      2022 – 2025
    • Research Category
      Grant-in-Aid for Challenging Research (Pioneering)
    • Review Section
      Medium-sized Section 50:Oncology and related fields
    • Research Institution
      Japanese Foundation for Cancer Research
  •  Molecular mechanisms of paradoxical growth suppression by over activation of oncogene kinasesPrincipal Investigator

    • Principal Investigator
      KATAYAMA Ryohei
    • Project Period (FY)
      2020 – 2021
    • Research Category
      Grant-in-Aid for Challenging Research (Exploratory)
    • Review Section
      Medium-sized Section 50:Oncology and related fields
    • Research Institution
      Japanese Foundation for Cancer Research
  •  Physicochemical factors required for the maintenance of genetic information in clinical cancer and their application to personalized cancer care

    • Principal Investigator
      Matsusaki Michiya
    • Project Period (FY)
      2020 – 2023
    • Research Category
      Grant-in-Aid for Scientific Research (A)
    • Review Section
      Medium-sized Section 90:Biomedical engineering and related fields
    • Research Institution
      Osaka University
  •  Analysis of the drug persistent cells to understand the acquired resistance mechanisms in lung cancerPrincipal Investigator

    • Principal Investigator
      KATAYAMA Ryohei
    • Project Period (FY)
      2019 – 2021
    • Research Category
      Grant-in-Aid for Scientific Research (B)
    • Review Section
      Basic Section 50020:Tumor diagnostics and therapeutics-related
    • Research Institution
      Japanese Foundation for Cancer Research
  •  Development of a novel therapy for colorectal cancers based on the gene mutation profiles.

    • Principal Investigator
      Nagayama Satoshi
    • Project Period (FY)
      2018 – 2020
    • Research Category
      Grant-in-Aid for Scientific Research (C)
    • Review Section
      Basic Section 50010:Tumor biology-related
    • Research Institution
      Japanese Foundation for Cancer Research
  •  Integrated analysis and regulation of cellular diversity for disease treatment

    • Principal Investigator
      FUJITA Naoya
    • Project Period (FY)
      2017 – 2021
    • Research Category
      Grant-in-Aid for Scientific Research on Innovative Areas (Research in a proposed research area)
    • Review Section
      Complex systems
    • Research Institution
      Japanese Foundation for Cancer Research
  •  Discovery of drug resistant mechnism by kinome analysis using patient derived cultured cells

    • Principal Investigator
      Tomonaga Takeshi
    • Project Period (FY)
      2016 – 2018
    • Research Category
      Grant-in-Aid for Scientific Research (B)
    • Research Field
      Tumor diagnostics
    • Research Institution
      National Institutes of Biomedical Innovation, Health and Nutrition
  •  Drug resistance mechanisms and therapeutic strategies in rare driver oncogene positive cancersPrincipal Investigator

    • Principal Investigator
      Katayama Ryohei
    • Project Period (FY)
      2016 – 2018
    • Research Category
      Grant-in-Aid for Scientific Research (B)
    • Research Field
      Tumor therapeutics
    • Research Institution
      Japanese Foundation for Cancer Research
  •  Mutual exclusiveness of driver oncogenesPrincipal Investigator

    • Principal Investigator
      KATAYAMA Ryohei
    • Project Period (FY)
      2015 – 2016
    • Research Category
      Grant-in-Aid for Challenging Exploratory Research
    • Research Field
      Tumor therapeutics
    • Research Institution
      Japanese Foundation for Cancer Research
  •  Discovery of druggable targets of colorectal cancers by genomic analysis with cancer stem-like cells

    • Principal Investigator
      Nagayama Satoshi
    • Project Period (FY)
      2014 – 2016
    • Research Category
      Grant-in-Aid for Scientific Research (C)
    • Research Field
      Tumor biology
    • Research Institution
      Japanese Foundation for Cancer Research
  •  Resistance mechanisms to molecular targeted drugs in lung adenocarcinomaPrincipal Investigator

    • Principal Investigator
      Katayama Ryohei
    • Project Period (FY)
      2013 – 2015
    • Research Category
      Grant-in-Aid for Young Scientists (A)
    • Research Field
      Tumor therapeutics
    • Research Institution
      Japanese Foundation for Cancer Research
  •  Investigation of the targeted therapy for cancer stem cellsPrincipal Investigator

    • Principal Investigator
      KATAYAMA Ryohei
    • Project Period (FY)
      2007 – 2008
    • Research Category
      Grant-in-Aid for Young Scientists (B)
    • Research Field
      Pathological medical chemistry
    • Research Institution
      Japanese Foundation For Cancer Research
  •  Molecular therapeutics targeting drug-resistance mechanisms

    • Principal Investigator
      TOMIDA Akihiro, 鶴尾 隆
    • Project Period (FY)
      2005 – 2009
    • Research Category
      Grant-in-Aid for Scientific Research on Priority Areas
    • Review Section
      Biological Sciences
    • Research Institution
      Japanese Foundation For Cancer Research
      The University of Tokyo

All 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2010 2009 2008 2007 2005 Other

All Journal Article Presentation Book Patent Other

  • [Book] Therapeutic Strategies to Overcome ALK Resistance in Cancer, Volume 13 1st Edition2020

    • Author(s)
      Luc Friboulet, Ryohei Katayama, et al
    • Total Pages
      216
    • Publisher
      Academic Press
    • ISBN
      9780128217740
    • Data Source
      KAKENHI-PROJECT-19H03524
  • [Book] Therapeutic Strategies to Overcome ALK Resistance in Cancer, Volume 13 1st Edition2020

    • Author(s)
      Luc Friboulet, Ryohei Katayama, et al
    • Total Pages
      216
    • Publisher
      Academic Press
    • ISBN
      9780128217740
    • Data Source
      KAKENHI-PROJECT-20K21554
  • [Book] Cancer Stem Cellの分離方法2009

    • Author(s)
      片山量平、藤田直也、金芳堂
    • Publisher
      癌分子標的治療研究実践マニュアル20章
    • Data Source
      KAKENHI-PROJECT-19790241
  • [Book] がん幹細胞-22008

    • Author(s)
      片山量平,鶴尾隆、藤田直也南山堂
    • Publisher
      癌の分子標的治療29章
    • Data Source
      KAKENHI-PROJECT-19790241
  • [Book] 癌の分子標的治療 第29章 「がん幹細胞-2」2008

    • Author(s)
      片山 量平
    • Total Pages
      7
    • Publisher
      南山堂
    • Data Source
      KAKENHI-PROJECT-19790241
  • [Journal Article] Adaptive resistance to lorlatinib via EGFR signaling in ALK-rearranged lung cancer2023

    • Author(s)
      Katayama Y, Yamada T, Tanimura K, Tokuda S, Morimoto K, Hirai S, Matsui Y, Nakamura R, Ishida M, Kawachi H, Yoneda K, Hosoya K, Tsuji T, Ozasa H, Yoshimura A, Iwasaku M, Kim YH, Horinaka M, Sakai T, Utsumi T, Shiotsu S, Takeda T, Katayama R, Takayama K
    • Journal Title

      npj Precision Oncology

      Volume: 7 Issue: 1 Pages: 12-12

    • DOI

      10.1038/s41698-023-00350-7

    • Peer Reviewed / Open Access
    • Data Source
      KAKENHI-PROJECT-22K18407, KAKENHI-PROJECT-19H01079, KAKENHI-PROJECT-19H03889, KAKENHI-PROJECT-22K18383
  • [Journal Article] Ultra‐Rapid and Specific Gelation of Collagen Molecules for Transparent and Tough Gels by Transition Metal Complexation2023

    • Author(s)
      Suezawa Tomoyuki、Sasaki Naoko、Yukawa Yuichi、Assan Nazgul、Uetake Yuta、Onuma Kunishige、Kamada Rino、Tomioka Daisuke、Sakurai Hidehiro、Katayama Ryohei、Inoue Masahiro、Matsusaki Michiya
    • Journal Title

      Advanced Science

      Volume: 10 Issue: 30 Pages: 20232637-20232637

    • DOI

      10.1002/advs.202302637

    • Peer Reviewed / Open Access
    • Data Source
      KAKENHI-PROJECT-22K05095, KAKENHI-PROJECT-22K19918, KAKENHI-PLANNED-22H05141, KAKENHI-PROJECT-20H00665
  • [Journal Article] Soluble PD-L1 works as a decoy in lung cancer immunotherapy via alternative polyadenylation2022

    • Author(s)
      Sagawa Ray、Sakata Seiji、Gong Bo、Seto Yosuke、Takemoto Ai、Takagi Satoshi、Ninomiya Hironori、Yanagitani Noriko、Nakao Masayuki、Mun Mingyon、Uchibori Ken、Nishio Makoto、Miyazaki Yasunari、Shiraishi Yuichi、Ogawa Seishi、Kataoka Keisuke、Fujita Naoya、Takeuchi Kengo、Katayama Ryohei
    • Journal Title

      JCI Insight

      Volume: 7 Issue: 1 Pages: 1-19

    • DOI

      10.1172/jci.insight.153323

    • Peer Reviewed / Open Access / Int'l Joint Research
    • Data Source
      KAKENHI-PROJECT-20K21554, KAKENHI-PROJECT-20K16370, KAKENHI-PLANNED-17H06327, KAKENHI-PROJECT-19H05656, KAKENHI-PROJECT-19H03524, KAKENHI-PROJECT-20K07399
  • [Journal Article] HER3 activation contributes toward the emergence of ALK inhibitor-tolerant cells in ALK-rearranged lung cancer with mesenchymal features.2022

    • Author(s)
      Tanimura K, Yamada T, Okada K, Nakai K, Horinaka M, Katayama Y, Morimoto K, Ogura Y, Takeda T, Shiotsu S, Ichikawa K, Watanabe S, Morimoto Y, Iwasaku M, Kaneko Y, Uchino J, Taniguchi H, Yoneda K, Matoba S, Sakai T, Uehara H, Yano S, Kusaba T, Katayama R, Takayama K.
    • Journal Title

      NPJ Precis Oncol.

      Volume: 6 Issue: 1 Pages: 5-5

    • DOI

      10.1038/s41698-021-00250-8

    • Peer Reviewed / Open Access
    • Data Source
      KAKENHI-PROJECT-19K08608, KAKENHI-PROJECT-20K21554, KAKENHI-PROJECT-20K22820, KAKENHI-PLANNED-17H06398, KAKENHI-PROJECT-19H01079, KAKENHI-PROJECT-19H03524, KAKENHI-PROJECT-19H03889, KAKENHI-PROJECT-20K08640
  • [Journal Article] Hitting the target in HER2 mutant cancers2022

    • Author(s)
      Katayama Ryohei
    • Journal Title

      Nature Cancer

      Volume: 3 Issue: 7 Pages: 785-786

    • DOI

      10.1038/s43018-022-00386-x

    • Peer Reviewed
    • Data Source
      KAKENHI-PROJECT-22K18383
  • [Journal Article] Fibroblast growth factor receptor 3 overexpression mediates <scp>ALK</scp> inhibitor resistance in <scp>ALK</scp> ‐rearranged non?small cell lung cancer2022

    • Author(s)
      Sakashita Takuya、Yanagitani Noriko、Koike Sumie、Low Siew‐Kee、Takagi Satoshi、Baba Satoko、Takeuchi Kengo、Nishio Makoto、Fujita Naoya、Katayama Ryohei
    • Journal Title

      Cancer Science

      Volume: 113 Issue: 11 Pages: 3888-3900

    • DOI

      10.1111/cas.15529

    • Peer Reviewed / Open Access
    • Data Source
      KAKENHI-PROJECT-22K18383
  • [Journal Article] GSK3 inhibition circumvents and overcomes acquired lorlatinib resistance in ALK-rearranged non-small-cell lung cancer2022

    • Author(s)
      Shimizu Yuki、Okada Koutaroh、Adachi Jun、Abe Yuichi、Narumi Ryohei、Uchibori Ken、Yanagitani Noriko、Koike Sumie、Takagi Satoshi、Nishio Makoto、Fujita Naoya、Katayama Ryohei
    • Journal Title

      npj Precision Oncology

      Volume: 6 Issue: 1 Pages: 16-16

    • DOI

      10.1038/s41698-022-00260-0

    • Peer Reviewed / Open Access
    • Data Source
      KAKENHI-PROJECT-20K21554, KAKENHI-PLANNED-17H06327, KAKENHI-PROJECT-19H03524, KAKENHI-PROJECT-20K07333, KAKENHI-ORGANIZER-17H06324, KAKENHI-PROJECT-23K20389
  • [Journal Article] Acquired resistance to BRAF inhibitors is mediated by BRAF splicing variants in BRAF V600E mutation-positive colorectal neuroendocrine carcinoma2022

    • Author(s)
      Shimizu Yuki、Maruyama Kohei、Suzuki Mai、Kawachi Hiroshi、Low Siew-Kee、Oh-hara Tomoko、Takeuchi Kengo、Fujita Naoya、Nagayama Satoshi、Katayama Ryohei
    • Journal Title

      Cancer Letters

      Volume: 543 Pages: 215799-215799

    • DOI

      10.1016/j.canlet.2022.215799

    • Peer Reviewed
    • Data Source
      KAKENHI-PROJECT-22K18383
  • [Journal Article] Chromatin structure-dependent histone incorporation revealed by a genome-wide deposition assay2021

    • Author(s)
      Hiroaki Tachiwana, Mariko Dacher, Kazumitsu Maehara, Akihito Harada, Yosuke Seto, Ryohei Katayama, Yasuyuki Ohkawa, Hiroshi Kimura, Hitoshi Kurumizaka, Noriko Saitoh
    • Journal Title

      eLife

      Volume: 10

    • DOI

      10.7554/elife.66290

    • Peer Reviewed / Open Access
    • Data Source
      KAKENHI-PUBLICLY-19H04970, KAKENHI-PUBLICLY-20H05393, KAKENHI-PROJECT-19H03158, KAKENHI-PROJECT-20K21398, KAKENHI-PROJECT-20K21554, KAKENHI-PROJECT-20K16370, KAKENHI-PLANNED-18H05527, KAKENHI-PLANNED-18H05534, KAKENHI-PUBLICLY-20H04846, KAKENHI-PUBLICLY-20H05397, KAKENHI-PUBLICLY-21H00232, KAKENHI-PUBLICLY-21H00430, KAKENHI-PROJECT-20H00449, KAKENHI-PROJECT-20H00456, KAKENHI-PROJECT-19H03211, KAKENHI-PROJECT-19H03524, KAKENHI-PROJECT-20H03520, KAKENHI-PROJECT-20K06496, KAKENHI-PROJECT-16H06279, KAKENHI-PLANNED-18H05531
  • [Journal Article] Monitoring epidermal growth factor receptor C797S mutation in Japanese non?small cell lung cancer patients with serial cell‐free DNA evaluation using digital droplet PCR2021

    • Author(s)
      Ariyasu Ryo、Uchibori Ken、Sasaki Takaaki、Tsukahara Mika、Kiyotani Kazuma、Yoshida Ryohei、Ono Yusuke、Kitazono Satoru、Ninomiya Hironori、Ishikawa Yuichi、Mizukami Yusuke、Yanagitani Noriko、Fujita Naoya、Nishio Makoto、Katayama Ryohei
    • Journal Title

      Cancer Science

      Volume: - Issue: 6 Pages: 2371-2380

    • DOI

      10.1111/cas.14879

    • Peer Reviewed / Open Access / Int'l Joint Research
    • Data Source
      KAKENHI-PROJECT-19H03446, KAKENHI-PROJECT-18K15936, KAKENHI-PROJECT-20K21554, KAKENHI-PLANNED-17H06327, KAKENHI-PROJECT-19H03522, KAKENHI-PROJECT-19H03524, KAKENHI-PROJECT-20K07671
  • [Journal Article] Microsecond-timescale MD simulation of EGFR minor mutation predicts the structural flexibility of EGFR kinase core that reflects EGFR inhibitor sensitivity2021

    • Author(s)
      Yoshizawa Takahiro、Uchibori Ken、Araki Mitsugu、Matsumoto Shigeyuki、Ma Biao、Kanada Ryo、Seto Yosuke、Oh-hara Tomoko、Koike Sumie、Ariyasu Ryo、Kitazono Satoru、Ninomiya Hironori、Takeuchi Kengo、Yanagitani Noriko、Takagi Satoshi、Kishi Kazuma、Fujita Naoya、Okuno Yasushi、Nishio Makoto、Katayama Ryohei
    • Journal Title

      npj Precision Oncology

      Volume: 5 Issue: 1 Pages: 32-32

    • DOI

      10.1038/s41698-021-00170-7

    • Peer Reviewed / Open Access / Int'l Joint Research
    • Data Source
      KAKENHI-PROJECT-19K22572, KAKENHI-PROJECT-18K15936, KAKENHI-PROJECT-18K06594, KAKENHI-PROJECT-20K21554, KAKENHI-PROJECT-20K16370, KAKENHI-PLANNED-17H06327, KAKENHI-PROJECT-19H03524
  • [Journal Article] Platelet-derived lysophosphatidic acid mediated LPAR1 activation as a therapeutic target for osteosarcoma metastasis2021

    • Author(s)
      Takagi Satoshi、Sasaki Yuki、Koike Sumie、Takemoto Ai、Seto Yosuke、Haraguchi Mizuki、Ukaji Takao、Kawaguchi Tokuichi、Sugawara Minoru、Saito Masanori、Funauchi Yuki、Ae Keisuke、Matsumoto Seiichi、Fujita Naoya、Katayama Ryohei
    • Journal Title

      Oncogene

      Volume: 40 Issue: 36 Pages: 5548-5558

    • DOI

      10.1038/s41388-021-01956-6

    • Peer Reviewed / Open Access
    • Data Source
      KAKENHI-PROJECT-20K21554, KAKENHI-PROJECT-20K16370, KAKENHI-PLANNED-17H06327, KAKENHI-PROJECT-19H03524, KAKENHI-ORGANIZER-17H06324
  • [Journal Article] Novel knock-in mouse model for the evaluation of the therapeutic efficacy and toxicity of human podoplanin-targeting agents.2021

    • Author(s)
      Ukaji T, Takemoto A, Shibata H, Kakino M, Takagi S, Katayama R, Fujita N
    • Journal Title

      Cancer Science

      Volume: In press Issue: 6 Pages: 2299-2313

    • DOI

      10.1111/cas.14891

    • Peer Reviewed / Open Access
    • Data Source
      KAKENHI-PROJECT-18K07216, KAKENHI-PROJECT-19K22572, KAKENHI-PLANNED-17H06327
  • [Journal Article] Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer2021

    • Author(s)
      Mizuta Hayato、Okada Koutaroh、Araki Mitsugu、Adachi Jun、Takemoto Ai、Kutkowska Justyna、Maruyama Kohei、Friboulet Luc、Katayama Kazuhiro、Ma Biao、Sasakura Yoko、Sagae Yukari、Kukimoto-Niino Mutsuko、Shirouzu Mikako、Takagi Satoshi、Simizu Siro、Nishio Makoto、Okuno Yasushi、Fujita Naoya、Katayama Ryohei, et al
    • Journal Title

      Nature Communications

      Volume: 12 Issue: 1 Pages: 1261-1261

    • DOI

      10.1038/s41467-021-21396-w

    • Peer Reviewed / Open Access / Int'l Joint Research
    • Data Source
      KAKENHI-PROJECT-20K21554, KAKENHI-PLANNED-17H06327, KAKENHI-PROJECT-19H03524, KAKENHI-PROJECT-18K06137, KAKENHI-PROJECT-19K22572, KAKENHI-PROJECT-18K06594, KAKENHI-ORGANIZER-17H06324
  • [Journal Article] Efficacy of EGFR tyrosine kinase inhibitors in patients having EGFR-activating mutations with or without BIM polymorphisms2020

    • Author(s)
      Ariyasu Ryo、Yanagitani Noriko、Tadokoro Kenichi、Yamaguchi Toshikazu、Uchibori Ken、Kitazono Satoru、Fujita Naoya、Katayama Ryohei、Nishio Makoto
    • Journal Title

      Cancer Chemotherapy and Pharmacology

      Volume: 86 Issue: 4 Pages: 517-525

    • DOI

      10.1007/s00280-020-04136-7

    • Peer Reviewed
    • Data Source
      KAKENHI-PROJECT-20K21554, KAKENHI-PLANNED-17H06327, KAKENHI-PROJECT-19H03524
  • [Journal Article] Improvement in predicting drug sensitivity changes associated with protein mutations using a molecular dynamics based alchemical mutation method.2020

    • Author(s)
      Ono F, Chiba S, Isaka Y, Matsumoto S, Ma B, Katayama R, Araki M, Okuno Y.
    • Journal Title

      Scientific Reports

      Volume: 10 Issue: 1 Pages: 2161-2161

    • DOI

      10.1038/s41598-020-58877-9

    • Peer Reviewed / Open Access
    • Data Source
      KAKENHI-PROJECT-19H03524
  • [Journal Article] U.S. Phase I First-in-human Study of Taletrectinib (DS-6051b/AB-106), a ROS1/TRK Inhibitor, in Patients with Advanced Solid Tumors2020

    • Author(s)
      Papadopoulos Kyriakos P.、Borazanci Erkut、Shaw Alice T.、Katayama Ryohei、Shimizu Yuki、Zhu Viola W.、Sun Thomas Yang、Wakelee Heather A.、Madison Russell、Schrock Alexa B.、Senaldi Giorgio、Nakao Naoki、Hanzawa Hiroyuki、Tachibana Masaya、Isoyama Takeshi、Seto Takashi、Janne Pasi A.、Ou Sai-Hong Ignatius et al
    • Journal Title

      Clinical Cancer Research

      Volume: 26 Issue: 18 Pages: 4785-4794

    • DOI

      10.1158/1078-0432.ccr-20-1630

    • Peer Reviewed / Open Access / Int'l Joint Research
    • Data Source
      KAKENHI-PROJECT-19H03524
  • [Journal Article] Drug resistance mechanisms in Japanese anaplastic lymphoma kinase‐positive non?small cell lung cancer and the clinical responses based on the resistant mechanisms2020

    • Author(s)
      Yanagitani N、Uchibori K、Koike S、Tsukahara、Kitazono、Yoshizawa、Horiike、Ohyanagi、Tambo、Nishikawa、Fujita、Katayama、Nishio M.
    • Journal Title

      Cancer Science

      Volume: 111 Issue: 3 Pages: 932-939

    • DOI

      10.1111/cas.14314

    • Peer Reviewed / Open Access
    • Data Source
      KAKENHI-PROJECT-15H02368, KAKENHI-PROJECT-19H03524, KAKENHI-PLANNED-17H06327
  • [Journal Article] Overcoming resistance by ALK compound mutation (I1171S + G1269A) after sequential treatment of multiple ALK inhibitors in non‐small cell lung cancer2020

    • Author(s)
      Takahashi、Seto、Okada、Uematsu、Uchibori、Tsukahara、Oh‐hara、Fujita、Yanagitani、Nishio、Okubo、Katayama R.
    • Journal Title

      Thoracic Cancer

      Volume: 11 Issue: 3 Pages: 581-587

    • DOI

      10.1111/1759-7714.13299

    • Peer Reviewed / Open Access
    • Data Source
      KAKENHI-PROJECT-15H02368, KAKENHI-PROJECT-19H03524, KAKENHI-PROJECT-20K16370
  • [Journal Article] Osimertinib Overcomes Alectinib Resistance Caused by Amphiregulin in a Leptomeningeal Carcinomatosis Model of ALK-Rearranged Lung Cancer.2020

    • Author(s)
      Sachiko Arai, Shinji Takeuchi, Koji Fukuda, Hirokazu Taniguchi, Akihiro Nishiyama, Azusa Tanimoto, Miyako Satouchi, Kaname Yamashita, Koshiro Ohtsubo, Shigeki Nanjo, Toru Kumagai, Ryohei Katayama, Makoto Nishio, Mei-Mei Zheng, Yi-Long Wu, Hiroshi Nishihara, Takushi Yamamoto, Mitsutoshi Nakada, Seiji Yano
    • Journal Title

      Journal of thoracic oncology

      Volume: 15 Issue: 5 Pages: 752-765

    • DOI

      10.1016/j.jtho.2020.01.001

    • Peer Reviewed / Open Access / Int'l Joint Research
    • Data Source
      KAKENHI-PROJECT-17K09649, KAKENHI-PROJECT-19K16738, KAKENHI-PROJECT-19H03524
  • [Journal Article] The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models2019

    • Author(s)
      Katayama R、Bo G、Togashi N、Miyamoto M、Kiga M、Iwasaki S、Kamai Y、Tominaga Y、Takeda Y、Kagoshima Y、Shimizu Y、Seto Y、Oh-hara T、Koike S、Nakao N、Hanzawa H、Watanabe K、Yoda S、Yanagitani N、Hata AN.、Shaw AT、Nishio M、Fujita N、Isoyama T.
    • Journal Title

      Nature Communications

      Volume: 10 Issue: 1 Pages: 3604-3604

    • DOI

      10.1038/s41467-019-11496-z

    • Peer Reviewed / Open Access / Int'l Joint Research
    • Data Source
      KAKENHI-ORGANIZER-17H06324, KAKENHI-PLANNED-17H06327, KAKENHI-PROJECT-15H02368, KAKENHI-PROJECT-19H03524
  • [Journal Article] Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistance2019

    • Author(s)
      Okada Koutaroh、Araki Mitsugu、Sakashita Takuya、Ma Biao、Kanada Ryo、Yanagitani Noriko、Horiike Atsushi、Koike Sumie、Oh-hara Tomoko、Watanabe Kana、Tamai Keiichi、Maemondo Makoto、Nishio Makoto、Ishikawa Takeshi、Okuno Yasushi、Fujita Naoya、Katayama Ryohei
    • Journal Title

      EBioMedicine

      Volume: 41 Pages: 105-119

    • DOI

      10.1016/j.ebiom.2019.01.019

    • NAID

      120006892063

    • Peer Reviewed / Open Access
    • Data Source
      KAKENHI-PROJECT-18K11536, KAKENHI-ORGANIZER-17H06324, KAKENHI-PLANNED-17H06327, KAKENHI-PROJECT-15H02368, KAKENHI-PROJECT-16H05840, KAKENHI-PROJECT-16K00397, KAKENHI-PROJECT-16H04715, KAKENHI-PROJECT-16H06276
  • [Journal Article] Epithelial-to-Mesenchymal Transition Is a Mechanism of ALK Inhibitor Resistance in Lung Cancer Independent of ALK Mutation Status.2019

    • Author(s)
      Fukuda K, Takeuchi S,Yano S, et al.
    • Journal Title

      Cancer Res

      Volume: 79(7) Issue: 7 Pages: 1658-1670

    • DOI

      10.1158/0008-5472.can-18-2052

    • Peer Reviewed / Open Access / Int'l Joint Research
    • Data Source
      KAKENHI-PROJECT-16H05308, KAKENHI-PROJECT-16H04715, KAKENHI-PROJECT-17K09649, KAKENHI-PROJECT-19K07346, KAKENHI-PROJECT-19H03665
  • [Journal Article] Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non-small cell lung cancer2019

    • Author(s)
      Gong Bo, Kiyotani Kazuma, Sakata Seiji, Nagano Seiji, Kumehara Shun, Baba Satoko, Besse Benjamin, Yanagitani Noriko, Friboulet Luc, Nishio Makoto, Takeuchi Kengo, Kawamoto Hiroshi, Fujita Naoya, Katayama Ryohei
    • Journal Title

      The Journal of Experimental Medicine

      Volume: 216 Issue: 4 Pages: 982-1000

    • DOI

      10.1084/jem.20180870

    • Peer Reviewed / Open Access / Int'l Joint Research
    • Data Source
      KAKENHI-PROJECT-17K07205, KAKENHI-PROJECT-16H04715, KAKENHI-PROJECT-16H06276, KAKENHI-ORGANIZER-17H06324, KAKENHI-PLANNED-17H06327, KAKENHI-PROJECT-19H03522, KAKENHI-PROJECT-18K19485
  • [Journal Article] A safety study of newly generated anti-podoplanin-neutralizing antibody in cynomolgus monkey (Macaca fascicularis).2018

    • Author(s)
      Ukaji T, Takemoto A, Katayama R, Takeuchi K, Fujita N
    • Journal Title

      Oncotarget

      Volume: 9 Issue: 70 Pages: 33322-33336

    • DOI

      10.18632/oncotarget.26055

    • Peer Reviewed / Open Access
    • Data Source
      KAKENHI-PROJECT-18K07216, KAKENHI-ORGANIZER-17H06324, KAKENHI-PLANNED-17H06327
  • [Journal Article] Recurrent 8q24 rearrangement in blastic plasmacytoid dendritic cell neoplasm: association with immunoblastoid cytomorphology, MYC expression, and drug response.2018

    • Author(s)
      Kana Sakamoto, Ryohei Katayama, Reimi Asaka, Seiji Sakata, Satoko Baba, Hideki Nakasone, Sumie Koike, Naoko Tsuyama, Akito Dobashi, Makoto Sasaki, Ryo Ichinohasama, Emi Takakuwa, Rie Yamazaki, Jun Takizawa, Takahiro Maeda, Miwako Narita, Koji Izutsu, Yoshinobu Kanda, Koichi Ohshima and Kengo Takeuchi
    • Journal Title

      Leukemia

      Volume: 32 Issue: 12 Pages: 2590-2603

    • DOI

      10.1038/s41375-018-0154-5

    • Peer Reviewed / Open Access
    • Data Source
      KAKENHI-PLANNED-17H06327, KAKENHI-PROJECT-17K18338, KAKENHI-PROJECT-16H04715, KAKENHI-PROJECT-16H06276
  • [Journal Article] Identification of mutation accumulation as resistance mechanism emerging in first-line osimertinib treatment.2018

    • Author(s)
      Ken Uchibori, Naohiko Inase, Makoto Nishio, Naoya Fujita, Ryohei Katayama
    • Journal Title

      J. Thorac. Oncol.

      Volume: 13 Issue: 7 Pages: 915-925

    • DOI

      10.1016/j.jtho.2018.04.005

    • Peer Reviewed / Open Access
    • Data Source
      KAKENHI-ORGANIZER-17H06324, KAKENHI-PLANNED-17H06327, KAKENHI-PROJECT-15H02368, KAKENHI-PROJECT-16H04715
  • [Journal Article] High ratio of T790M to EGFR activating mutations correlate with the osimertinib response in non-small-cell lung cancer2018

    • Author(s)
      Ariyasu Ryo、Nishikawa Shingo、Uchibori Ken、Oh-hara Tomoko、Yoshizawa Takahiro、Dotsu Yosuke、Koyama Junji、Saiki Masafumi、Sonoda Tomoaki、Kitazono Satoru、Yanagitani Noriko、Horiike Atsushi、Inase Naohiko、Kasahara Kazuo、Nishio Makoto、Katayama Ryohei
    • Journal Title

      Lung Cancer

      Volume: 117 Pages: 1-6

    • DOI

      10.1016/j.lungcan.2017.12.018

    • Peer Reviewed
    • Data Source
      KAKENHI-PROJECT-17K09606, KAKENHI-PROJECT-16H04715, KAKENHI-PLANNED-17H06327
  • [Journal Article] Drug resistance in anaplastic lymphoma kinase-rearranged lung cancer2018

    • Author(s)
      Katayama Ryohei
    • Journal Title

      Cancer Science

      Volume: 109 Issue: 3 Pages: 572-580

    • DOI

      10.1111/cas.13504

    • Peer Reviewed / Open Access
    • Data Source
      KAKENHI-PROJECT-16H04715, KAKENHI-PLANNED-17H06327
  • [Journal Article] 3D culture system containing gellan gum restores oncogene dependence in ROS1 rearrangements non-small cell lung cancer.2018

    • Author(s)
      Bo Gong, Tomoko Oh-hara, Naoya Fujita, Ryohei Katayama
    • Journal Title

      Biochem. Biophys. Res. Commun.

      Volume: 501 Issue: 2 Pages: 527-533

    • DOI

      10.1016/j.bbrc.2018.05.031

    • Peer Reviewed / Open Access
    • Data Source
      KAKENHI-PLANNED-17H06327, KAKENHI-PROJECT-15H02368, KAKENHI-PROJECT-16H04715, KAKENHI-PROJECT-16H06276
  • [Journal Article] 8. Mechanisms of resistance to NTRK inhibitors and therapeutic strategies in NTRK1-rearranged cancers.2017

    • Author(s)
      Miho Jane Fuse, Koutaroh Okada, Tomoko Oh-hara, Hayato Ogura, Naoya Fujita, Ryohei Katayama
    • Journal Title

      Mol Cancer Ther.

      Volume: 16 Issue: 10 Pages: 2130-2143

    • DOI

      10.1158/1535-7163.mct-16-0909

    • Peer Reviewed / Open Access
    • Data Source
      KAKENHI-ORGANIZER-17H06324, KAKENHI-PLANNED-17H06327, KAKENHI-PROJECT-15H02368, KAKENHI-PROJECT-16H04715
  • [Journal Article] Therapeutic strategies and mechanisms of drug resistance in anaplastic lymphoma kinase (ALK)-rearranged lung cancer.2017

    • Author(s)
      Katayama R
    • Journal Title

      Pharmacology & Therapeutics

      Volume: in press Pages: 1-8

    • DOI

      10.1016/j.pharmthera.2017.02.015

    • Peer Reviewed / Acknowledgement Compliant
    • Data Source
      KAKENHI-PROJECT-16H04715, KAKENHI-PROJECT-15K14412
  • [Journal Article] APC mutations as a predictive biomarker for sensitivity to tankyrase inhibitors in colorectal cancer.2017

    • Author(s)
      Noritaka Tanaka, Tetsuo Mashima, Anna Mizutani, Ayana Sato, Aki Aoyama, Bo Gong, Haruka Yoshida, Yukiko Muramatsu, Kento Nakata, Masaaki Matsuura, Ryohei Katayama, Satoshi Nagayama, Naoya Fujita, Yoshikazu Sugimoto, Hiroyuki Seimiya
    • Journal Title

      Mol. Cancer Ther.

      Volume: 16 Issue: 4 Pages: 739-751

    • DOI

      10.1158/1535-7163.mct-16-0578

    • Peer Reviewed / Open Access
    • Data Source
      KAKENHI-PROJECT-15H02368, KAKENHI-PROJECT-16H04715, KAKENHI-PROJECT-16H04716, KAKENHI-PROJECT-26430177, KAKENHI-PROJECT-15K14409, KAKENHI-PROJECT-15K14412
  • [Journal Article] TKI-addicted ROS1-rearranged cells are destined to survival or death by the intensity of ROS1 kinase activity2017

    • Author(s)
      Hayato Ogura, Yuka Nagatake-Kobayashi, Jun Adachi, Takeshi Tomonaga, Naoya Fujita, Ryohei Katayama
    • Journal Title

      Sci. Rep.

      Volume: 7 Issue: 1 Pages: 5519-5519

    • DOI

      10.1038/s41598-017-05736-9

    • Peer Reviewed / Open Access
    • Data Source
      KAKENHI-ORGANIZER-17H06324, KAKENHI-PLANNED-17H06327, KAKENHI-PROJECT-15H02368, KAKENHI-PROJECT-16H04707, KAKENHI-PROJECT-16H04715
  • [Journal Article] Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer.2017

    • Author(s)
      Ken Uchibori, Naohiko Inase, Mitsugu Araki, Mayumi Kamada, Shigeo Sato, Yasushi Okuno, Naoya Fujita, Ryohei Katayama
    • Journal Title

      Nature Commun.

      Volume: 8 Issue: 1 Pages: 14768-14768

    • DOI

      10.1038/ncomms14768

    • NAID

      120006027079

    • Peer Reviewed / Acknowledgement Compliant / Open Access
    • Data Source
      KAKENHI-PROJECT-15H02368, KAKENHI-PROJECT-16H04715, KAKENHI-PROJECT-15K14412, KAKENHI-ORGANIZER-17H06324
  • [Journal Article] P-glycoprotein mediates ceritinib resistance in anaplastic lymphoma kinase-rearranged non-small cell lung cancer.2016

    • Author(s)
      Katayama R*, Sakashita T, Yanagitani N, Ninomiya H, Horiike A, Friboulet L, Gainor JF, Motoi N, Dobashi A, Sakata S, Tambo Y, Kitazono S, Sato S, Koike S, Iafrate AJ, Mino-Kenudson M, Ishikawa Y, Shaw AT, Engelman JA, Takeuchi K, Nishio M*, Fujita N*
    • Journal Title

      EBioMedicine

      Volume: 3 Pages: 54-66

    • DOI

      10.1016/j.ebiom.2015.12.009

    • Peer Reviewed / Acknowledgement Compliant / Open Access / Int'l Joint Research
    • Data Source
      KAKENHI-PROJECT-15K14412, KAKENHI-PROJECT-15H02368, KAKENHI-PROJECT-25250020, KAKENHI-PROJECT-25710015, KAKENHI-PROJECT-15K08373
  • [Journal Article] Crizotinib Resensitization by the Lorlatinib ALK L1198F Resistance Mutation.2016

    • Author(s)
      Shaw AT, Friboulet L, Leshchiner I, Gainor JF, Bergqvist S, Brooun A, Burke BJ, Deng YL, Liu W, Dardaei L, Frias RL, Schultz KR, Logan J, James LP, Smeal T, Timofeevski S, Katayama R, Iafrate AJ, Le L, McTigue M, Getz G, Johnson TW, Engelman JA.
    • Journal Title

      New Engl J Med

      Volume: 374 Issue: 1 Pages: 54-61

    • DOI

      10.1056/nejmoa1508887

    • Peer Reviewed / Int'l Joint Research
    • Data Source
      KAKENHI-PROJECT-25710015
  • [Journal Article] Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.2016

    • Author(s)
      Gainor JF, Dardaei L, Yoda S, Friboulet L, Leshchiner I, Katayama R, Engelman JA, Shaw AT, et al.
    • Journal Title

      Cancer Discovery

      Volume: 6 Issue: 10 Pages: 1118-1133

    • DOI

      10.1158/2159-8290.cd-16-0596

    • Peer Reviewed / Int'l Joint Research
    • Data Source
      KAKENHI-PROJECT-16H04715, KAKENHI-PROJECT-15K14412
  • [Journal Article] Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: a paradigm for precision cancer medicine.2015

    • Author(s)
      Katayama R*, Lovly CM, Shaw AT
    • Journal Title

      Clinical Cancer Research

      Volume: 21 Issue: 10 Pages: 2227-2235

    • DOI

      10.1158/1078-0432.ccr-14-2791

    • Peer Reviewed / Int'l Joint Research
    • Data Source
      KAKENHI-PROJECT-15K14412, KAKENHI-PROJECT-25710015
  • [Journal Article] Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer.2015

    • Author(s)
      Katayama R, Kobayashi Y, Friboulet L, Lockerman EL, Koike S, Shaw AT, Engelman JA, Fujita N.
    • Journal Title

      Clinical Cancer Research

      Volume: 21 Issue: 1 Pages: 166-174

    • DOI

      10.1158/1078-0432.ccr-14-1385

    • Peer Reviewed / Acknowledgement Compliant
    • Data Source
      KAKENHI-PROJECT-25710015
  • [Journal Article] RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer.2015

    • Author(s)
      Niederst MJ, Sequist LV, Poirier JT, Mermel CH, Lockerman EL, Garcia AR, Katayama R, Costa C, Ross KN, Moran T, Howe E, Fulton LE, Mulvey HE, Bernardo LA, Mohamoud F, Miyoshi N, VanderLaan PA, Costa DB, Jänne PA, Borger DR, Ramaswamy S, Shioda T, Iafrate AJ, Getz G, Rudin CM, Mino-Kenudson M, Engelman JA.
    • Journal Title

      Nature Communications

      Volume: 11 Issue: 1 Pages: 6377-6377

    • DOI

      10.1038/ncomms7377

    • Peer Reviewed / Open Access
    • Data Source
      KAKENHI-PROJECT-25710015
  • [Journal Article] PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models.2015

    • Author(s)
      Zou HY, Friboulet L, Kodack DP, Engstrom LD, Li Q, West M, Tang RW, Wang H, Tsaparikos K, Wang J, Timofeevski S, Katayama R, Dinh DM, Lam H, Lam JL, Yamazaki S, Hu W, Patel B, Bezwada D, Frias RL, Lifshits E, Mahmood S, Gainor JF, Affolter T, Lappin PB, Jain RK, Johnson TW, Shaw AT, Fantin VR, Smeal T, et al.
    • Journal Title

      Cancer Cell

      Volume: 28 Issue: 1 Pages: 70-81

    • DOI

      10.1016/j.ccell.2015.05.010

    • Peer Reviewed / Int'l Joint Research
    • Data Source
      KAKENHI-PROJECT-25710015
  • [Journal Article] Patient-derived models of acquired resistance can identify effective drug combinations for cancer.2014

    • Author(s)
      Crystal AS, Shaw AT, Sequist LV, Friboulet L, Niederst MJ, Lockerman EL, Frias RL, Gainor JF, Amzallag A, Greninger P, Lee D, Kalsy A, Gomez-Caraballo M, Elamine L, Howe E, Hur W, Lifshits E, Robinson HE, Katayama R, Faber AC, Awad MM, Ramaswamy S, Mino-Kenudson M, Iafrate AJ, Benes CH, Engelman JA.
    • Journal Title

      Science

      Volume: 346 Issue: 6216 Pages: 1480-1486

    • DOI

      10.1126/science.1254721

    • Peer Reviewed
    • Data Source
      KAKENHI-PROJECT-25710015
  • [Journal Article] Tivantinib (ARQ 197) exhibits antitumor activity by directly interacting with tubulin and overcomes ABC transporter–mediated drug resistance.2014

    • Author(s)
      Aki Aoyama, Ryohei Katayama, Tomoko Oh-hara, Shigeo Sato, Yasushi Okuno and Naoya Fujita
    • Journal Title

      Mol. Cancer Ther.

      Volume: 13 Issue: 12 Pages: 2978-2990

    • DOI

      10.1158/1535-7163.mct-14-0462

    • Peer Reviewed / Acknowledgement Compliant
    • Data Source
      KAKENHI-PROJECT-24300344, KAKENHI-PROJECT-25710015
  • [Journal Article] Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib.2014

    • Author(s)
      Ryohei Katayama, Luc Friboulet, Sumie Koike, Elizabeth L. Lockerman, Tahsin M. Khan, Justin F. Gainor, A. John Iafrate, Kengo Takeuchi, Makoto Taiji, Yasushi Okuno, Naoya Fujita, Jeffrey A. Engelman, Alice T. Shaw
    • Journal Title

      Clin. Cancer Res.

      Volume: 20 Issue: 22 Pages: 5686-5696

    • DOI

      10.1158/1078-0432.ccr-14-1511

    • Peer Reviewed / Acknowledgement Compliant
    • Data Source
      KAKENHI-PROJECT-24300344, KAKENHI-PROJECT-25250020, KAKENHI-PROJECT-25710015
  • [Journal Article] The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer.2014

    • Author(s)
      Friboulet L, Li N, Katayama R, Lee CC, Gainor JF, Crystal AS, Michellys PY, Awad MM, Yanagitani N, Kim S, Pferdekamper AC, Li J, Kasibhatla S, Sun F, Sun X, Hua S, McNamara P, Mahmood S, Lockerman EL, Fujita N, Nishio M, Harris JL, Shaw AT, Engelman JA
    • Journal Title

      Cancer Discov.

      Volume: 4 Issue: 6 Pages: 662-673

    • DOI

      10.1158/2159-8290.cd-13-0846

    • Peer Reviewed
    • Data Source
      KAKENHI-PROJECT-24300344, KAKENHI-PROJECT-25710015
  • [Journal Article] Modulation of Wnt signaling by the nuclear localization of cellular FLIP-L2010

    • Author(s)
      Katayama R
    • Journal Title

      J Cell Sci 123

      Pages: 23-28

    • Peer Reviewed
    • Data Source
      KAKENHI-PROJECT-17016012
  • [Journal Article] Dofequidar fumarate sensitizes cancer stem-like side population cells to chemotherapeutic drugs by inhibiting ABCG2/BCRP-mediated drug export2009

    • Author(s)
      Katayama R, Koike S, Sato S, Sugimoto Y, Tsuruo T, Fujita N.
    • Journal Title

      Cancer Sci. 100

      Pages: 2060-8

    • NAID

      10027196750

    • Peer Reviewed
    • Data Source
      KAKENHI-PROJECT-17016012
  • [Journal Article] Dofequidar fumarate sensitizes cancer stem-like side population cells to chemotherapeutic drugs by inhibiting ABCG2/BCRP-mediated drug export2009

    • Author(s)
      Katayama R
    • Journal Title

      Cancer Sci 100

      Pages: 2060-2068

    • Peer Reviewed
    • Data Source
      KAKENHI-PROJECT-17016012
  • [Journal Article] Pim kinases promote cell cycle progression by phosphorylating and down-regulating p27Kip1 at the transcriptional and posttranscriptional levels2008

    • Author(s)
      Morishita D, Katayama R, Sekimizu K, Tsuruo T, Fujita N.
    • Journal Title

      Cancer Res. 68

      Pages: 5076-85

    • Peer Reviewed
    • Data Source
      KAKENHI-PROJECT-17016012
  • [Journal Article] FOXO transcription factor-dependent p15(INK4b) and p19(INK4d)expression.2008

    • Author(s)
      Katayama K
    • Journal Title

      Oncogene 13

      Pages: 1677-86

    • Peer Reviewed
    • Data Source
      KAKENHI-PROJECT-17016012
  • [Journal Article] TUSC4/NPRL2, a novel PDK1-interacting protein, inhibits PDK1 tyrosine phosphorylation and its downstream signaling2008

    • Author(s)
      Kurata A, Katayama R, Watanabe T, Tsuruo T, Fujita N.
    • Journal Title

      Cancer Sci. 99

      Pages: 1827-34

    • NAID

      10024011166

    • Peer Reviewed
    • Data Source
      KAKENHI-PROJECT-17016012
  • [Journal Article] FOXO transcription factor-dependent p15(INK4b) and p19(INK4d) expression2008

    • Author(s)
      Katayama K, Nakamura A, Sugimoto Y, Tsuruo T, Fujita N.
    • Journal Title

      Oncogene 27

      Pages: 1677-86

    • Peer Reviewed
    • Data Source
      KAKENHI-PROJECT-17016012
  • [Journal Article] Impairment of the ubiquitin-proteasome system by cellular FLIP2007

    • Author(s)
      Ishioka T, Katayama R, Kikuchi R, Nishimoto M, Takada S, Takada R, Matsuzawa S, Reed JC, Tsuruo T, Naito M.
    • Journal Title

      Genes Cells. 12

      Pages: 735-44

    • Peer Reviewed
    • Data Source
      KAKENHI-PROJECT-17016012
  • [Journal Article] Casein kinase 2-interacting protein-1, a novel Akt pleckstrin homology domain-interacting protein, down-regulates PI3K/Akt signaling and suppresses tumor growth in vivo2007

    • Author(s)
      Tokuda E, Fujita N, Oh-hara T, Sato S, Kurata A, Katayama R, Itoh T, Takenawa T, Miyazono K, Tsuruo T.
    • Journal Title

      Cancer Res. 67

      Pages: 9666-76

    • Peer Reviewed
    • Data Source
      KAKENHI-PROJECT-17016012
  • [Journal Article] Akt/protein kinase B-dependent phosphorylation and inactivation of WEE1 Hu promote cell cycle progression at G_2/M transition.2005

    • Author(s)
      Katayama, K., et al.
    • Journal Title

      Mol.Cell.Biol. 25

      Pages: 5725-5737

    • Data Source
      KAKENHI-PROJECT-17016012
  • [Patent] 薬物徐放性を血小板に付与する細胞デザイナー分子2023

    • Inventor(s)
      松崎典弥、仲本正 彦、片山量平
    • Industrial Property Rights Holder
      松崎典弥、仲本正 彦、片山量平
    • Industrial Property Rights Type
      特許
    • Industrial Property Number
      2023-029675
    • Filing Date
      2023
    • Data Source
      KAKENHI-PROJECT-20H00665
  • [Patent] ギルテリチニブの種々の変異体に対する適用2021

    • Inventor(s)
      片山量平
    • Industrial Property Rights Holder
      公益財団法人がん研究会
    • Industrial Property Rights Type
      特許
    • Industrial Property Number
      2021-020640
    • Filing Date
      2021
    • Data Source
      KAKENHI-PROJECT-19H03524
  • [Patent] 長時間分子動力学シミュレーションによる変異型タンパク質に対する治療薬探索法2021

    • Inventor(s)
      片山量平、荒木望嗣、奥野恭史
    • Industrial Property Rights Holder
      公益財団法人がん研究会、国立大学法人京都大学
    • Industrial Property Rights Type
      特許
    • Industrial Property Number
      2021-066780
    • Filing Date
      2021
    • Data Source
      KAKENHI-PROJECT-20K21554
  • [Patent] ギルテリチニブの種々の変異体に対する適用2021

    • Inventor(s)
      片山量平
    • Industrial Property Rights Holder
      公益財団法人がん研究会
    • Industrial Property Rights Type
      特許
    • Industrial Property Number
      2021-020640
    • Filing Date
      2021
    • Data Source
      KAKENHI-PROJECT-20K21554
  • [Patent] 長時間分子動力学シミュレーションによる変異型タンパク質に対する治療薬探索法2021

    • Inventor(s)
      片山量平、荒木望嗣、奥野恭史
    • Industrial Property Rights Holder
      公益財団法人がん研究会、国立大学法人京都大学
    • Industrial Property Rights Type
      特許
    • Industrial Property Number
      2021-066780
    • Filing Date
      2021
    • Data Source
      KAKENHI-PROJECT-19H03524
  • [Patent] EGFR-TKI耐性を獲得した肺癌の治療薬2016

    • Inventor(s)
      片山量平、内堀健、藤田直也
    • Industrial Property Rights Holder
      公益財団法人がん研究会
    • Industrial Property Rights Type
      特許
    • Filing Date
      2016-12-06
    • Data Source
      KAKENHI-PROJECT-15K14412
  • [Patent] EGFR-TKI耐性を獲得した肺癌の治療薬2016

    • Inventor(s)
      片山量平、内堀健、藤田直也
    • Industrial Property Rights Holder
      公益財団法人がん研究会
    • Industrial Property Rights Type
      特許
    • Filing Date
      2016-12-06
    • Data Source
      KAKENHI-PROJECT-16H04715
  • [Patent] RET阻害薬耐性癌に対する治療剤2014

    • Inventor(s)
      矢野聖二、竹内伸司、藤田直也、片山量平
    • Industrial Property Rights Holder
      矢野聖二、竹内伸司、藤田直也、片山量平
    • Industrial Property Rights Type
      特許
    • Filing Date
      2014-10-31
    • Data Source
      KAKENHI-PROJECT-25710015
  • [Presentation] 阻害剤ライブラリーと Crispr スクリーニングによる肺がん薬剤耐性機構の探索2022

    • Author(s)
      片山量平
    • Organizer
      第63回日本肺癌学会学術集会
    • Invited
    • Data Source
      KAKENHI-PROJECT-22K18383
  • [Presentation] バイパス経路活性化を生むリガンドの供給源と受容体活性化機構の探索2022

    • Author(s)
      片山量平
    • Organizer
      第63回日本肺癌学会学術集会
    • Invited
    • Data Source
      KAKENHI-PROJECT-22K18383
  • [Presentation] NRG1融合遺伝子陽性大腸がんにおけるFISH法を用いた検出法の確立と新規治療薬候補の同定2022

    • Author(s)
      鈴木麻衣, 丸山航平, 大原智子, 坂田征士, 竹内賢吾, 藤田直也, 長山聡,片山量平
    • Organizer
      第81回日本癌学会学術総会
    • Data Source
      KAKENHI-PROJECT-22K18383
  • [Presentation] 薬剤耐性腫瘍における腫瘍内シグナル伝達の可塑性と多様性2022

    • Author(s)
      片山量平
    • Organizer
      第81回日本癌学会学術総会
    • Invited
    • Data Source
      KAKENHI-PROJECT-22K18383
  • [Presentation] EGFR マイナー変異の薬剤感受性の検討2022

    • Author(s)
      大原智子, 鈴木麻衣, 片山量平
    • Organizer
      第81回日本癌学会学術総会
    • Data Source
      KAKENHI-PROJECT-22K18383
  • [Presentation] KRAS変異大腸がん患者検体を用いた変異型KRAS特異的阻害薬への初期耐性メカニズムの探索2022

    • Author(s)
      丸山航平, 鈴木麻衣, 大原智子, 長山聡, 藤田直也, 片山量平
    • Organizer
      第81回日本癌学会学術総会
    • Data Source
      KAKENHI-PROJECT-22K18383
  • [Presentation] 再発がん患者検体と初代培養がん細胞を用いた薬剤耐性機構と耐性克服法の探索2021

    • Author(s)
      片山量平
    • Organizer
      2020年度日本学術会議・日本薬学会主催シンポジウム「創薬を加速させる革新的な細胞・臓器・個体モデル」
    • Invited
    • Data Source
      KAKENHI-PROJECT-19H03524
  • [Presentation] L747P mutation in EGFR mediates the resistance to gefitinib and allosteric inhibitor by losing αC-helix flexibility2021

    • Author(s)
      大原智子、藤田直也、西尾誠人、片山量平
    • Organizer
      第80回 日本癌学会学術総会
    • Data Source
      KAKENHI-PROJECT-20K21554
  • [Presentation] Diverse drug resistance mechanisms and overcoming the resistance by drug repurposing2021

    • Author(s)
      片山量平、藤田直也
    • Organizer
      第80回 日本癌学会学術総会
    • Invited
    • Data Source
      KAKENHI-PROJECT-19H03524
  • [Presentation] Diverse drug resistance mechanisms and overcoming the resistance by drug repurposing2021

    • Author(s)
      片山量平、藤田直也
    • Organizer
      第80回 日本癌学会学術総会
    • Invited
    • Data Source
      KAKENHI-PROJECT-20K21554
  • [Presentation] 活性化血小板由来LPAはLPAR1活性化を介して骨肉腫の肺転移を促進する2021

    • Author(s)
      高木聡、小池清恵、藤田直也、片山量平
    • Organizer
      第25回日本がんがん分子標的治療学会
    • Data Source
      KAKENHI-PLANNED-17H06327
  • [Presentation] Mechanisms of drug resistance cultivated in tumor microenvironments2021

    • Author(s)
      片山量平
    • Organizer
      the 39th Sapporo International Cancer Symposium
    • Invited / Int'l Joint Research
    • Data Source
      KAKENHI-PROJECT-20K21554
  • [Presentation] Diverse drug resistance mechanisms and overcoming the resistance by drug repurposing2021

    • Author(s)
      片山量平、藤田直也
    • Organizer
      第80回日本癌学会学術総会
    • Invited
    • Data Source
      KAKENHI-PLANNED-17H06327
  • [Presentation] Osteosarcoma promotes pulmonary metastasis via the release of lysophosphatidic acid from activated platelets2021

    • Author(s)
      高木 聡、小池 清恵、竹本 愛、菅原 稔、藤田 直也、片山 量平
    • Organizer
      第80回日本癌学会学術総会
    • Data Source
      KAKENHI-PLANNED-17H06327
  • [Presentation] L747P mutation in EGFR mediates the resistance to gefitinib and allosteric inhibitor by losing αC-helix flexibility2021

    • Author(s)
      大原智子、藤田直也、西尾誠人、片山量平
    • Organizer
      第80回 日本癌学会学術総会
    • Data Source
      KAKENHI-PROJECT-19H03524
  • [Presentation] がん分子標的治療とがん免疫チェックポイント阻害薬に対する獲得耐性機構の基礎研究2021

    • Author(s)
      片山量平
    • Organizer
      第95回日本癌治療学会学術集会
    • Invited
    • Data Source
      KAKENHI-PROJECT-20K21554
  • [Presentation] L747P mutation in EGFR mediates the resistance to gefitinib and allosteric inhibitor by losing αC-helix flexibility2021

    • Author(s)
      大原智子、藤田直也、西尾誠人、片山量平
    • Organizer
      第80回日本癌学会学術総会
    • Data Source
      KAKENHI-PLANNED-17H06327
  • [Presentation] Mechanisms of drug resistance cultivated in tumor microenvironments2021

    • Author(s)
      片山量平
    • Organizer
      the 39th Sapporo International Cancer Symposium
    • Invited / Int'l Joint Research
    • Data Source
      KAKENHI-PROJECT-19H03524
  • [Presentation] FLT3阻害薬ギルテリチニブによる 多剤耐性ALK陽性肺がんの克服2021

    • Author(s)
      水田隼斗、高木聡、竹本愛、西尾誠人、藤田直也、清水史郎、片山量平
    • Organizer
      第25回日本がん分子標的治療学術集会
    • Data Source
      KAKENHI-PROJECT-20K21554
  • [Presentation] Identification of molecular targets in early-onset colorectal cancers by sequencing and drug screening2021

    • Author(s)
      鈴木麻衣、清水裕貴、丸山航平、大原智子、藤田直也、長山聡、片山量平
    • Organizer
      第80回日本癌学会学術総会
    • Data Source
      KAKENHI-PLANNED-17H06327
  • [Presentation] FLT3阻害薬ギルテリチニブによる 多剤耐性ALK陽性肺がんの克服2021

    • Author(s)
      水田隼斗、高木聡、竹本愛、西尾誠人、藤田直也、清水史郎、片山量平
    • Organizer
      第25回日本がん分子標的治療学術集会
    • Data Source
      KAKENHI-PROJECT-19H03524
  • [Presentation] FLT3阻害薬ギルテリチニブは多剤耐性ALK陽性肺がんの耐性を克服する2021

    • Author(s)
      水田隼斗、高木聡、竹本愛、西尾誠人、藤田直也、清水史郎、片山量平
    • Organizer
      第25回日本がんがん分子標的治療学会
    • Data Source
      KAKENHI-PLANNED-17H06327
  • [Presentation] Intrinsic and acquired resistances to kinase inhibitors and immune checkpoint inhibitors in NSCLC2021

    • Author(s)
      片山量平
    • Organizer
      第62回 日本肺癌学会学術集会
    • Invited
    • Data Source
      KAKENHI-PROJECT-20K21554
  • [Presentation] Identification of the achilles heels of colorectal cancer cells harboring BRAF V600E mutation by focused inhibitor library screening2021

    • Author(s)
      清水裕貴、丸山航平、鈴木麻衣、大原智子、高橋祐生、長山聡、藤田直也、片山量平
    • Organizer
      第80回日本癌学会学術総会
    • Data Source
      KAKENHI-PLANNED-17H06327
  • [Presentation] がん分子標的治療とがん免疫チェックポイント阻害薬に対する獲得耐性機構の基礎研究2021

    • Author(s)
      片山量平
    • Organizer
      第95回日本癌治療学会学術集会
    • Invited
    • Data Source
      KAKENHI-PROJECT-19H03524
  • [Presentation] Stubborn cancers: Molecular mechanisms to the targeted cancer therapy2021

    • Author(s)
      片山量平
    • Organizer
      第25回日本がん分子標的治療学術集会
    • Invited
    • Data Source
      KAKENHI-PROJECT-20K21554
  • [Presentation] Intrinsic and acquired resistances to kinase inhibitors and immune checkpoint inhibitors in NSCLC2021

    • Author(s)
      片山量平
    • Organizer
      第62回 日本肺癌学会学術集会
    • Invited
    • Data Source
      KAKENHI-PROJECT-19H03524
  • [Presentation] Mechanisms of intrinsic resistance mediated by tumor microenvironment and secreted proteins in non-small cell lung cancer2021

    • Author(s)
      Ryohei Katayama, Naoya Fujita
    • Organizer
      第1回 JCA-AACR precision oncology
    • Invited / Int'l Joint Research
    • Data Source
      KAKENHI-PROJECT-20K21554
  • [Presentation] Discovery of the FLT3 inhibitor gilteritinib as a novel therapeutic strategy to overcome ALK-TKI resistance2021

    • Author(s)
      水田隼斗、竹本愛、高木聡、清水史郎、西尾誠人、藤田直也、片山量平
    • Organizer
      第80回日本癌学会学術総会
    • Data Source
      KAKENHI-PLANNED-17H06327
  • [Presentation] Potential therapeutic strategies for overcoming intrinsic and acquired resistance in ALK+NSCLC2021

    • Author(s)
      Ryohei Katayama
    • Organizer
      第25回がん研究会-国際がん化学療法シンポジウム
    • Invited / Int'l Joint Research
    • Data Source
      KAKENHI-PROJECT-19H03524
  • [Presentation] 再発がん患者検体と初代培養がん細胞を用いた薬剤耐性機構と耐性克服法の探索2021

    • Author(s)
      片山量平
    • Organizer
      2020年度日本学術会議・日本薬学会主催シンポジウム「創薬を加速させる革新的な細胞・臓器・個体モデル」
    • Invited
    • Data Source
      KAKENHI-PROJECT-20K21554
  • [Presentation] Identification of intrinsic resistance mechanisms to KRAS-G12C specific inhibitor using patient derived colorectal cancer cells2021

    • Author(s)
      丸山航平、清水裕貴、鈴木麻衣、大原智子、藤田直也、長山聡、片山量平
    • Organizer
      第80回日本癌学会学術総会
    • Data Source
      KAKENHI-PLANNED-17H06327
  • [Presentation] Mechanisms of intrinsic resistance mediated by tumor microenvironment and secreted proteins in non-small cell lung cancer2021

    • Author(s)
      Ryohei Katayama, Naoya Fujita
    • Organizer
      第1回 JCA-AACR precision oncology
    • Invited / Int'l Joint Research
    • Data Source
      KAKENHI-PROJECT-19H03524
  • [Presentation] Discovery of the FLT3 inhibitor gilteritinib as a novel therapeutic strategy to overcome ALK-TKI resistance2021

    • Author(s)
      水田隼斗、竹本愛、高木聡、清水史郎、西尾誠人、藤田直也、片山量平
    • Organizer
      第80回 日本癌学会学術総会
    • Data Source
      KAKENHI-PROJECT-19H03524
  • [Presentation] Stubborn cancers: Molecular mechanisms to the targeted cancer therapy2021

    • Author(s)
      片山量平
    • Organizer
      第25回日本がん分子標的治療学術集会
    • Invited
    • Data Source
      KAKENHI-PROJECT-19H03524
  • [Presentation] Potential therapeutic strategies for overcoming intrinsic and acquired resistance in ALK+NSCLC2021

    • Author(s)
      Ryohei Katayama
    • Organizer
      第25回がん研究会-国際がん化学療法シンポジウム
    • Invited / Int'l Joint Research
    • Data Source
      KAKENHI-PROJECT-20K21554
  • [Presentation] Discovery of the FLT3 inhibitor gilteritinib as a novel therapeutic strategy to overcome ALK-TKI resistance2021

    • Author(s)
      水田隼斗、竹本愛、高木聡、清水史郎、西尾誠人、藤田直也、片山量平
    • Organizer
      第80回 日本癌学会学術総会
    • Data Source
      KAKENHI-PROJECT-20K21554
  • [Presentation] Targeting drug persistent and resistant cells in driver mutation positive cancer2020

    • Author(s)
      片山量平、藤田直也
    • Organizer
      第79回日本癌学会学術総会
    • Invited
    • Data Source
      KAKENHI-PROJECT-20K21554
  • [Presentation] 手術検体からのKRAS G12C 変異大腸がん細胞株の樹立と新規併用療法の探索2020

    • Author(s)
      丸山航平、清水裕貴、大原智子、長山聡、藤田直也、片山量平
    • Organizer
      第79回日本癌学会学術総会
    • Data Source
      KAKENHI-PLANNED-17H06327
  • [Presentation] 薬剤感受性プロファイリングを用いた大腸がん患者由来細胞の特性解析2020

    • Author(s)
      清水 裕貴、丸山 航平、キョウ博、高橋 祐生、藤田 直也、長山 聡、片山 量平
    • Organizer
      先端モデル動物支援プラットフォーム 成果発表会
    • Data Source
      KAKENHI-PROJECT-19H03524
  • [Presentation] Targeting drug persistent and resistant cells in driver mutation positive cancer2020

    • Author(s)
      片山量平、藤田直也
    • Organizer
      第79回日本癌学会学術総会
    • Invited
    • Data Source
      KAKENHI-PROJECT-19H03524
  • [Presentation] がん臨床検体を用いた免疫チェックポイント阻害薬耐性機構の探索と分泌型PD-L1バリアント2020

    • Author(s)
      片山量平、藤田直也
    • Organizer
      第24回日本がん分子標的治療学会学術集会
    • Invited
    • Data Source
      KAKENHI-PROJECT-19H03524
  • [Presentation] ALK rearranged NSCLC;prediction and simulation of the resistance mutations and therapeutic strategies2020

    • Author(s)
      片山量平
    • Organizer
      第61回日本肺癌学会学術集会
    • Invited
    • Data Source
      KAKENHI-PROJECT-19H03524
  • [Presentation] 薬剤耐性変異予測モデル構築に向けたALK-TKIの薬効評価2020

    • Author(s)
      水田隼斗、大原智子、小池清恵、岩見真吾、清水史郎、藤田直也、片山量平
    • Organizer
      第79回日本癌学会学術総会
    • Data Source
      KAKENHI-PLANNED-17H06327
  • [Presentation] Regulation of cellular diversity in tumor microenvironment by platelet activation-inducing molecule Podoplanin2020

    • Author(s)
      Satoshi Takagi, Ryohei Katayama, Ai Takemoto, Naoya Fujita
    • Organizer
      第43回日本分子生物学会年会
    • Invited
    • Data Source
      KAKENHI-PLANNED-17H06327
  • [Presentation] ALK rearranged NSCLC;prediction and simulation of the resistance mutations and therapeutic strategies2020

    • Author(s)
      片山量平
    • Organizer
      第61回日本肺癌学会学術集会
    • Invited
    • Data Source
      KAKENHI-PROJECT-20K21554
  • [Presentation] A unique ex vivo tumor model: 3D co-cultured system with cancer and stromal cells including blood microvessels.2020

    • Author(s)
      Yuki Takahashi, Kei Tsukamoto, Rii Morimura, Isana Nada, Yuki Shimizu, Ryohei Katayama, Eiji Shinozaki, Satoshi Nagayama, Michiya Matsusaki, Shiro Kitano, Kensei Yamaguchi, Naoya Fujita
    • Organizer
      ASCO-GI 2020
    • Int'l Joint Research
    • Data Source
      KAKENHI-PLANNED-17H06327
  • [Presentation] がん臨床検体を用いた免疫チェックポイント阻害薬耐性機構の探索と分泌型PD-L1バリアント2020

    • Author(s)
      片山量平、藤田直也
    • Organizer
      第24回日本がん分子標的治療学会
    • Invited
    • Data Source
      KAKENHI-PLANNED-17H06327
  • [Presentation] 分子プロファイルを用いたBRAF V600E変異陽性大腸がんに対する有効な薬剤の発見2020

    • Author(s)
      清水裕貴、丸山航平、瀬戸陽介、キョウ博、大原智子、高橋祐生、長山聡、藤田直也、片山量平
    • Organizer
      第79回日本癌学会学術総会
    • Data Source
      KAKENHI-PLANNED-17H06327
  • [Presentation] Identification of secreted PD-L1 variants as a decoy of PD-L1 blockade antibody mediating the therapeutic resistance.2019

    • Author(s)
      Bo Gong, Kazuma Kiyotani, Seiji Sakata, Ken Takahashi, Seiji Nagano, Shun Kumehara, Satoko Baba, Benjamin Besse, Noriko Yanagitani, Luc Friboulet, Makoto Nishio, Kengo Takeuchi, Hiroshi Kawamoto, Naoya Fujita, and Ryohei Katayama
    • Organizer
      2019 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
    • Int'l Joint Research
    • Data Source
      KAKENHI-PLANNED-17H06327
  • [Presentation] 分泌型PD-L1バリアントを介した免疫チェックポイント治療薬治療耐性機構の発見2019

    • Author(s)
      キョウ博、清谷一馬、坂田征士、西尾誠人、竹内賢吾、河本宏、藤田直也、片山量平
    • Organizer
      第78回日本癌学会学術総会
    • Invited
    • Data Source
      KAKENHI-PLANNED-17H06327
  • [Presentation] 次世代ROS1/NTRK阻害薬DS-6051bによるCrizotinib耐性の克服2019

    • Author(s)
      片山量平、キョウ博、西尾誠人、藤田直也
    • Organizer
      第78回日本癌学会学術総会
    • Data Source
      KAKENHI-PLANNED-17H06327
  • [Presentation] Evaluation of oncogenicity, kinase activity and drug sensitivity of lorlatinib resistant ALK-L1256F mutant.2019

    • Author(s)
      大原智子、藤田直也、片山量平
    • Organizer
      第78回 日本癌学会学術総会
    • Data Source
      KAKENHI-PROJECT-19H03524
  • [Presentation] がん免疫環境記憶モデルを利用したICI治療抵抗性因子のゲノムワイドスクリーニング2019

    • Author(s)
      原口瑞樹、キョウ博、瀬戸陽介、高橋和久、片山量平
    • Organizer
      先端モデル動物プラットフォーム 2019年度若手支援技術講習会
    • Data Source
      KAKENHI-PROJECT-19H03524
  • [Presentation] 血小板活性化因子PDPNを介した腫瘍免疫微小環境の制御2019

    • Author(s)
      高木聡、小池清恵、藤田直也、片山量平
    • Organizer
      第23回日本がん分子標的治療学会
    • Data Source
      KAKENHI-PLANNED-17H06327
  • [Presentation] ドライバーがん遺伝子の活性化変異が誘導する分子標的薬耐性と新たな脆弱性2019

    • Author(s)
      片山量平、岡田康太郎、藤田直也
    • Organizer
      第42回日本分子生物学会年会
    • Data Source
      KAKENHI-PLANNED-17H06327
  • [Presentation] Predication of lorlatinib resistance mechanisms and therapeutic strategies to overcome the resistance in ALK rearranged non-small cell lung cancer2019

    • Author(s)
      Koutaroh Okada, Mitsugu Araki, Tomoko Oh-hara, Makoto Nishio, Yasushi Okuno, Naoya Fujita, Ryohei Katayama
    • Organizer
      2019 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
    • Data Source
      KAKENHI-PROJECT-19H03524
  • [Presentation] Similarity and difference of resistance mechanisms to TKIs and ICI in lung cancer2019

    • Author(s)
      片山量平、藤田直也
    • Organizer
      第23回日本がん分子標的治療学術集会
    • Invited
    • Data Source
      KAKENHI-PROJECT-19H03524
  • [Presentation] Predication of lorlatinib resistance mechanisms and therapeutic strategies to overcome the resistance in ALK rearranged non-small cell lung cancer.2019

    • Author(s)
      Koutaroh Okada, Mitsugu Araki, Tomoko Oh-hara, Makoto Nishio, Yasushi Okuno, Naoya Fujita, Ryohei Katayama
    • Organizer
      2019 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
    • Int'l Joint Research
    • Data Source
      KAKENHI-PLANNED-17H06327
  • [Presentation] Targeting BRAF V600E mutant colorectal cancer by drug re-purposing2019

    • Author(s)
      清水裕貴、キョウ博、大原智子、長山聡、藤田直也、片山量平
    • Organizer
      第78回 日本癌学会学術総会
    • Data Source
      KAKENHI-PROJECT-19H03524
  • [Presentation] 肺がんのチロシンキナーゼ阻害薬耐性と免疫チェックポイント阻害薬耐性2019

    • Author(s)
      片山量平、藤田直也
    • Organizer
      第23回日本がん分子標的治療学会
    • Invited
    • Data Source
      KAKENHI-PLANNED-17H06327
  • [Presentation] 分泌型PD-L1スプライシングバリアントを介した免疫チェックポイント治療薬耐性機構の発見2019

    • Author(s)
      キョウ博、西尾誠人、藤田直也、片山量平
    • Organizer
      第23回日本がん分子標的治療学会
    • Data Source
      KAKENHI-PLANNED-17H06327
  • [Presentation] BRAF V600E変異陽性大腸がんに有効な既存薬の発見2019

    • Author(s)
      清水 裕貴、きょう 博、大原 智子、長山 聡、藤田 直也、片山 量平
    • Organizer
      第78回日本癌学会
    • Data Source
      KAKENHI-PROJECT-18K07218
  • [Presentation] Investigation of EMT-mediated anti-cancer drug resistance of cancer cells by single-cell RNA-seq analysis2019

    • Author(s)
      Yosuke Seto, Ryohei Katayama
    • Organizer
      SMBE 2019 “The annual conference of the society for molecular biology and evolution”
    • Int'l Joint Research
    • Data Source
      KAKENHI-PLANNED-17H06327
  • [Presentation] Crizotinib resistance mechanisms and potential therapeutic strategies to overcome the resistance in ROS1 rearranged non-small cell lung cancer.2019

    • Author(s)
      Ryohei Katayama, Bo Gong, Makoto Nishio, Naoya Fujita
    • Organizer
      2019 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
    • Data Source
      KAKENHI-PROJECT-19H03524
  • [Presentation] Development of a humanized anti-podoplanin antibody inhibiting tumor-dependent platelet activation.2019

    • Author(s)
      Ai Takemoto, Nobuhiko Gyobu, Mamoru Kakino, Shinya Fujihara, Naoki Goda, Junya Maeda, Miho Takami, Takao Ukaji, Satoshi Takagi, Ryohei Katayama, Kazue Tsuji-Takayama, Kenji Ichihara, Shinobu Nakayama, Yoshiyuki Ohsugi, and Naoya Fujita
    • Organizer
      The 24th ISCC Symposium
    • Int'l Joint Research
    • Data Source
      KAKENHI-PLANNED-17H06327
  • [Presentation] がんの進化と多様性により生み出される多様な治療抵抗性機構の解析2019

    • Author(s)
      片山量平、キョウ博、西尾誠人、藤田直也
    • Organizer
      第19回日本蛋白質科学会年会・第71回日本細胞生物学会大会 合同年次大会
    • Invited
    • Data Source
      KAKENHI-PLANNED-17H06327
  • [Presentation] Cellular diversity by genetic and non-genetic alteration in cancer induces acquired resistance in NSCLC.2019

    • Author(s)
      Ryohei Katayama, Bo Gong, Koutaroh Okada, Makoto Nishio, and Naoya Fujita
    • Organizer
      11th AACR-JCA Joint Conference on Breakthroughs in Cancer Research: Biology to Precision Medicine
    • Invited / Int'l Joint Research
    • Data Source
      KAKENHI-PROJECT-16H04715
  • [Presentation] DS-6051b, a next-generation ROS1/NTRK inhibitor overcomes crizotinib resistant ROS1-G2032R in preclinical models2019

    • Author(s)
      片山量平、キョウ博、西尾誠人、藤田直也
    • Organizer
      第78回 日本癌学会学術総会
    • Data Source
      KAKENHI-PROJECT-19H03524
  • [Presentation] 非接着培養を用いた新規ROS1阻害剤評価系の構築2018

    • Author(s)
      キョウ 博、大原 智子、小池 清恵、藤田 直也、片山 量平
    • Organizer
      第22回 日本がん分子標的治療学会学術総会
    • Data Source
      KAKENHI-PROJECT-16H04715
  • [Presentation] Anticancer drug resistance caused by cancer cell evolution and diversity2018

    • Author(s)
      片山 量平、藤田 直也
    • Organizer
      第41回日本分子生物学会年会
    • Invited
    • Data Source
      KAKENHI-PROJECT-16H04715
  • [Presentation] 肺がん分子標的薬耐性メカニズムの探索と耐性機構予測への挑戦2018

    • Author(s)
      片山 量平、岡田 康太郎、藤田 直也
    • Organizer
      第22回 日本がん分子標的治療学会学術総会
    • Invited
    • Data Source
      KAKENHI-PROJECT-16H04715
  • [Presentation] Detection, prediction, and investigation of the resistance mechanisms to EGFR-TKIs in EGFR mutated NSCLC2018

    • Author(s)
      片山 量平
    • Organizer
      第59回 日本肺癌学会学術集会
    • Invited
    • Data Source
      KAKENHI-PROJECT-16H04715
  • [Presentation] BRAF V600E変異陽性大腸がんにおける新たなサブグループの発見2018

    • Author(s)
      清水 裕貴、キョウ 博、大原 智子、長山 聡、藤田 直也、片山 量平
    • Organizer
      第77回日本癌学会学術総会
    • Data Source
      KAKENHI-PROJECT-16H04715
  • [Presentation] Prediction of TKI resistance in lung cancer through the experimental models and in silico simulations2018

    • Author(s)
      片山 量平、藤田 直也
    • Organizer
      第77回日本癌学会学術総会
    • Invited
    • Data Source
      KAKENHI-PROJECT-16H04715
  • [Presentation] Her2活性化変異陽性肺がん細胞株の樹立とキナーゼ阻害薬の評価2018

    • Author(s)
      大原 智子、藤田 直也、片山 量平
    • Organizer
      第77回 日本癌学会学術総会
    • Data Source
      KAKENHI-PROJECT-16H04715
  • [Presentation] Her2 活性化変異陽性肺がん細胞株の樹立とキナーゼ阻害薬の評価2018

    • Author(s)
      大原智子、藤田直也、片山量平
    • Organizer
      第77回 日本癌学会学術総会
    • Data Source
      KAKENHI-PLANNED-17H06327
  • [Presentation] 次世代ALK阻害薬Lorlatinib耐性重複変異の発見とその治療戦略の示唆2018

    • Author(s)
      岡田 康太郎、藤田 直也、片山 量平
    • Organizer
      第22回 日本がん分子標的治療学会学術総会
    • Data Source
      KAKENHI-PROJECT-16H04715
  • [Presentation] Drug repurposing: overcoming the acquired resistance with other target inhibitors2018

    • Author(s)
      Ryohei Katayama, Koutaroh Okada, Bo Gong, Ken Uchibori, Makoto Nishio, and Naoya Fujita
    • Organizer
      The 23th Taiwan Joint Cancer Conference 2018
    • Invited / Int'l Joint Research
    • Data Source
      KAKENHI-PROJECT-16H04715
  • [Presentation] 三次元培養システムによるRET再構成肺癌細胞の薬物感受性評価システムの確立2018

    • Author(s)
      小池 清恵、藤田 直也、片山 量平
    • Organizer
      第77回 日本癌学会学術総会
    • Data Source
      KAKENHI-PROJECT-16H04715
  • [Presentation] 初回治療オシメルチニブ後に予想される変異蓄積による獲得耐性機構2018

    • Author(s)
      内堀健、北園聡、柳谷典子、堀池篤、西尾誠人、稲瀬直彦、藤田直也、片山量平
    • Organizer
      肺癌学会
    • Data Source
      KAKENHI-PLANNED-17H06327
  • [Presentation] がんと血小板の結合を標的とする化合物の探索と解析2018

    • Author(s)
      竹本愛、片山量平、藤田直也
    • Organizer
      第77回 日本癌学会学術総会
    • Data Source
      KAKENHI-PLANNED-17H06327
  • [Presentation] ALK陽性肺がん獲得耐性から考えるキナーゼ進化2018

    • Author(s)
      片山 量平
    • Organizer
      第41回日本呼吸器内視鏡学会学術集会
    • Invited
    • Data Source
      KAKENHI-PROJECT-16H04715
  • [Presentation] BRAF V600E変異陽性大腸がんにおける新たなサブグループの発見2018

    • Author(s)
      清水裕貴、キョウ博、大原智子、長山聡、藤田直也、片山量平
    • Organizer
      第77回 日本癌学会学術総会
    • Data Source
      KAKENHI-PLANNED-17H06327
  • [Presentation] KRAS変異大腸がんにおける分子プロファイリングに基づく新規併用治療法の探索2018

    • Author(s)
      キョウ 博、清水 裕貴、大原 智子、長山 聡、藤田 直也、片山 量平
    • Organizer
      第77回 日本癌学会学術総会
    • Data Source
      KAKENHI-PROJECT-16H04715
  • [Presentation] Drug repurposing: overcoming the acquired resistance with other target inhibitors2018

    • Author(s)
      Ryohei Katayama, Bo Gong, Koutaroh Okada, Ken Uchibori, Makoto Nishio, and Naoya Fujita
    • Organizer
      6th JCA-AACR Joint Conference
    • Invited / Int'l Joint Research
    • Data Source
      KAKENHI-PROJECT-16H04715
  • [Presentation] KRAS変異大腸がんにおける分子プロファイリングに基づく新規併用治療法の探索2018

    • Author(s)
      キョウ博、清水裕貴、大原智子、長山聡、藤田直也、片山量平
    • Organizer
      第77回 日本癌学会学術総会
    • Data Source
      KAKENHI-PLANNED-17H06327
  • [Presentation] オシメルチニブ初回治療のシーケンスで予想される耐性機構としての多重変異について2018

    • Author(s)
      内堀健、西尾誠人、稲瀬直彦、藤田直也、片山量平
    • Organizer
      第16回 日本臨床腫瘍学会学術集会
    • Data Source
      KAKENHI-PLANNED-17H06327
  • [Presentation] Identification of the molecular mechanisms of resistance to NTRK inhibitors and the potential therapeutic strategies in NTRK1-rearranged cancers2017

    • Author(s)
      Ryohei Katayama, Miho Jane Fuse, Tomoko Oh-hara, Hayato Ogura, Naoya Fujita
    • Organizer
      AACR annual meeting
    • Int'l Joint Research
    • Data Source
      KAKENHI-PROJECT-16H04715
  • [Presentation] 1st and 2nd generation ALK-TKI rescues the next-generation ALK-TKI resistance mediated by double mutations2017

    • Author(s)
      Koutaroh Okada, Shigeo Sato, Naoya Fujita, Ryohei Katayama
    • Organizer
      第22回International Symposium on Cancer Chemotherapy
    • Int'l Joint Research
    • Data Source
      KAKENHI-PLANNED-17H06327
  • [Presentation] 13.Molecular Basis of TKI resistant cells in driver oncogene positive NSCLC2017

    • Author(s)
      片山量平
    • Organizer
      第58回日本肺癌学会学術集会
    • Invited
    • Data Source
      KAKENHI-PROJECT-16H04715
  • [Presentation] Driver Oncogene陽性肺がんにおける獲得耐性の分子基盤と新たな治療戦略2017

    • Author(s)
      片山量平、藤田直也
    • Organizer
      第76回 日本癌学会学術総会
    • Invited
    • Data Source
      KAKENHI-PLANNED-17H06327
  • [Presentation] Inhibitor deprivation mediated excessive oncogene signaling in drug resistant cancers induces both growth and apoptosis signaling.2017

    • Author(s)
      Hayato Ogura, Jun Adachi, Takeshi Tomonaga, Naoya Fujita, Ryohei Katayama
    • Organizer
      AACR 2017
    • Place of Presentation
      ワシントン, 米国
    • Year and Date
      2017-04-01
    • Int'l Joint Research
    • Data Source
      KAKENHI-PROJECT-15K14412
  • [Presentation] Overcoming the C797S/T790M mutation mediated Osimertinib resistance by Brigatinib combined with anti-EGFR antibody2017

    • Author(s)
      内堀健、藤田直也、片山量平
    • Organizer
      第75回日本癌学会学術総会
    • Data Source
      KAKENHI-PROJECT-16H04715
  • [Presentation] Analysis of “drug addiction” mechanisms in the drug-resistant ROS1-rearranged cancer cells2017

    • Author(s)
      Hayato Ogura, Jun Adachi, Takeshi Tomonaga, Naoya Fujita, Ryohei Katayama
    • Organizer
      AACR annual meeting
    • Int'l Joint Research
    • Data Source
      KAKENHI-PROJECT-16H04715
  • [Presentation] cMET増幅を介したALK阻害薬耐性とその克服法2017

    • Author(s)
      小池清恵、藤田直也、片山量平
    • Organizer
      第20回日本がん分子標的治療学会学術集会
    • Data Source
      KAKENHI-PROJECT-16H04715
  • [Presentation] 11.Drug Repurposing: Overcoming drug resistance mutation with tyrosine kinase inhibitor for different target2017

    • Author(s)
      片山量平、藤田直也
    • Organizer
      第15回日本臨床腫瘍学会学術集会
    • Invited
    • Data Source
      KAKENHI-PROJECT-16H04715
  • [Presentation] ドライバーがん遺伝子陽性がんにおける分子標的薬耐性機構とその検索2017

    • Author(s)
      片山量平
    • Organizer
      第1回Liquid Biopsy研究会
    • Place of Presentation
      東京
    • Year and Date
      2017-01-21
    • Invited
    • Data Source
      KAKENHI-PROJECT-15K14412
  • [Presentation] 10.Driver oncogene陽性肺がんにおける多様な分子標的薬耐性とその克服法2017

    • Author(s)
      片山量平、藤田直也
    • Organizer
      第20回日本がん分子標的治療学会学術集会
    • Invited
    • Data Source
      KAKENHI-PROJECT-16H04715
  • [Presentation] NTRK融合遺伝子陽性がんにおける獲得耐性機構2017

    • Author(s)
      大原智子、佐藤重男、藤田直也、片山量平
    • Organizer
      第75回日本癌学会学術総会
    • Data Source
      KAKENHI-PROJECT-16H04715
  • [Presentation] G1202R変異型EML4-ALKの変異蓄積による次世代ALK阻害剤Lorlatinib耐性の獲得2017

    • Author(s)
      岡田康太郎、藤田直也、片山量平
    • Organizer
      第20回日本がん分子標的治療学会学術集会
    • Data Source
      KAKENHI-PROJECT-16H04715
  • [Presentation] 12.Driver Oncogene陽性肺がんにおける獲得耐性の分子基盤と新たな治療戦略2017

    • Author(s)
      片山量平
    • Organizer
      第75回日本癌学会学術総会
    • Invited
    • Data Source
      KAKENHI-PROJECT-16H04715
  • [Presentation] Resistance mechanisms to NTRK-TKIs in NTRK1 rearranged cancer2017

    • Author(s)
      大原智子、佐藤重夫、藤田直也、片山量平
    • Organizer
      第76回 日本癌学会学術総会
    • Data Source
      KAKENHI-PLANNED-17H06327
  • [Presentation] ドライバーがん遺伝子陽性がんにおける分子標的薬耐性機構とその検索2017

    • Author(s)
      片山量平
    • Organizer
      第1回Liquid Biopsy研究会
    • Place of Presentation
      東京
    • Year and Date
      2017-01-21
    • Invited
    • Data Source
      KAKENHI-PROJECT-16H04715
  • [Presentation] ALK戦線異常アリ:多様なTKI耐性機構とその克服2016

    • Author(s)
      片山 量平
    • Organizer
      第57回日本肺癌学会学術集会
    • Place of Presentation
      福岡
    • Year and Date
      2016-12-19
    • Invited
    • Data Source
      KAKENHI-PROJECT-15K14412
  • [Presentation] FGFR3またはcMETの過剰活性化を介したALK阻害薬耐性機構の発見2016

    • Author(s)
      片山量平、小池清恵、大原智子、西尾誠人、藤田直也
    • Organizer
      第20回 日本がん分子標的治療学会学術総会
    • Place of Presentation
      大分県別府市
    • Year and Date
      2016-05-30
    • Data Source
      KAKENHI-PROJECT-16H04715
  • [Presentation] 肺がん臨床検体を用いた分子標的薬耐性機構の解明2016

    • Author(s)
      片山量平
    • Organizer
      平成27年度「がん研究分野の特性等を踏まえた支援活動」公開シンポジウム
    • Place of Presentation
      東京、学術総合センター
    • Year and Date
      2016-02-09
    • Invited
    • Data Source
      KAKENHI-PROJECT-25710015
  • [Presentation] Tumor cell and stromal cell mediated drug resistance in driver oncogene positive non-small cell lung cancer2016

    • Author(s)
      片山 量平
    • Organizer
      第74回日本癌学会学術総会
    • Place of Presentation
      横浜
    • Year and Date
      2016-10-06
    • Invited
    • Data Source
      KAKENHI-PROJECT-16H04715
  • [Presentation] Resistance mechanisms to tyrosine kinase inhibitors in fusion gene positive non-small cell lung cancer2016

    • Author(s)
      片山量平
    • Organizer
      Tenth AACR-JCA Joint Conference on Breakthroughs in Cancer Research: From Biology to Therapeutics
    • Place of Presentation
      米国、マウイ
    • Year and Date
      2016-02-14
    • Invited / Int'l Joint Research
    • Data Source
      KAKENHI-PROJECT-25710015
  • [Presentation] FGFR3またはcMETの過剰活性化を介したALK阻害薬耐性機構の発見2016

    • Author(s)
      Ryohei Katayama, Sumie Koike, Tomoko Oh-hara, Makoto Nishio, Naoya Fujita
    • Organizer
      第20回 日本がん分子標的治療学会学術総会
    • Place of Presentation
      大分県別府市
    • Year and Date
      2016-05-30
    • Data Source
      KAKENHI-PROJECT-15K14412
  • [Presentation] Tumor cell and stromal cell mediated drug resistance in driver oncogene positive non-small cell lung cance2016

    • Author(s)
      片山 量平
    • Organizer
      第74回日本癌学会学術総会
    • Place of Presentation
      横浜
    • Year and Date
      2016-10-06
    • Invited
    • Data Source
      KAKENHI-PROJECT-15K14412
  • [Presentation] 肺がん臨床検体を用いた分子標的薬耐性機構の解明2016

    • Author(s)
      片山量平
    • Organizer
      平成27年度「がん研究分野の特性等を踏まえた支援活動」公開シンポジウム
    • Place of Presentation
      東京、学術総合センター
    • Year and Date
      2016-02-09
    • Invited
    • Data Source
      KAKENHI-PROJECT-15K14412
  • [Presentation] ABCトランスポーターを介したALK阻害薬耐性2016

    • Author(s)
      小池清恵、藤田直也、片山量平
    • Organizer
      第20回 日本がん分子標的治療学会学術総会
    • Place of Presentation
      大分県別府市
    • Year and Date
      2016-05-30
    • Data Source
      KAKENHI-PROJECT-16H04715
  • [Presentation] TKI-resistance mechanisms in ALK or ROS1 rearranged non-small cell lung cancer.2016

    • Author(s)
      片山 量平
    • Organizer
      第14回日本臨床腫瘍学会学術集会
    • Place of Presentation
      兵庫県神戸市
    • Year and Date
      2016-07-28
    • Invited
    • Data Source
      KAKENHI-PROJECT-16H04715
  • [Presentation] ALK戦線異常アリ:多様なTKI耐性機構とその克服2016

    • Author(s)
      片山 量平
    • Organizer
      第57回日本肺癌学会学術集会
    • Place of Presentation
      福岡
    • Year and Date
      2016-12-19
    • Invited
    • Data Source
      KAKENHI-PROJECT-16H04715
  • [Presentation] Characterization of the ALK-TKI resistant cells mediated by secondary mutations or bypass pathway activation2015

    • Author(s)
      小池清恵、坂下卓也、西尾誠人、藤田直也、片山量平
    • Organizer
      第74回 日本癌学会総会
    • Place of Presentation
      名古屋国際会議場、名古屋
    • Year and Date
      2015-10-09
    • Data Source
      KAKENHI-PROJECT-15K14412
  • [Presentation] Characterization of the ALK-TKI resistant cells mediated by secondary mutations or bypass pathway activation.2015

    • Author(s)
      小池清恵、坂下卓也、西尾誠人、藤田直也、片山量平
    • Organizer
      第74回 日本癌学会総会
    • Place of Presentation
      名古屋国際会議場、名古屋
    • Year and Date
      2015-10-08
    • Data Source
      KAKENHI-PROJECT-25710015
  • [Presentation] 培養細胞株と患者検体を用いたALK阻害薬耐性機構の解析2015

    • Author(s)
      片山量平、小池清恵、西尾誠人、藤田直也
    • Organizer
      第19回日本がん分子標的治療学会
    • Place of Presentation
      松山全日空ホテル、愛媛
    • Year and Date
      2015-06-10
    • Data Source
      KAKENHI-PROJECT-15K14412
  • [Presentation] Molecular mechanism of the TKI resistance in lung cancer ~TKI-resistance in fusion gene driven lung cancer~2015

    • Author(s)
      片山 量平
    • Organizer
      第13回 日本臨床腫瘍学会学術総会
    • Place of Presentation
      ロイトン札幌、札幌
    • Year and Date
      2015-07-16
    • Invited
    • Data Source
      KAKENHI-PROJECT-15K14412
  • [Presentation] Novel ceritinib resistance mechanisms: new resistant mutation, fibroblast growth factor receptor 3 overexpression and cMET amplification-mediated ceritinib resistance2015

    • Author(s)
      Ryohei Katayama, Takuya Sakashita, Noriko Yanagitani, Kengo Takeuchi, Makoto Nishio, Naoya Fujita
    • Organizer
      AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
    • Place of Presentation
      米国、ボストン
    • Year and Date
      2015-11-05
    • Int'l Joint Research
    • Data Source
      KAKENHI-PROJECT-25710015
  • [Presentation] 培養細胞株と患者検体を用いたALK阻害薬耐性機構の解析2015

    • Author(s)
      片山量平、小池清恵、西尾誠人、藤田直也
    • Organizer
      第19回 日本がん分子標的治療学会
    • Place of Presentation
      松山全日空ホテル、愛媛
    • Year and Date
      2015-06-10
    • Data Source
      KAKENHI-PROJECT-25710015
  • [Presentation] Molecular mechanism of the TKI resistance in lung cancer ~TKI-resistance in fusion gene driven lung cancer~2015

    • Author(s)
      片山 量平
    • Organizer
      第13回 日本臨床腫瘍学会学術総会
    • Place of Presentation
      ロイトン札幌、札幌
    • Year and Date
      2015-07-16
    • Invited
    • Data Source
      KAKENHI-PROJECT-25710015
  • [Presentation] ALK阻害薬耐性の分子基盤2015

    • Author(s)
      片山量平
    • Organizer
      第56回日本肺癌学会学術集会
    • Place of Presentation
      パシフィコ横浜、横浜
    • Year and Date
      2015-11-26
    • Invited
    • Data Source
      KAKENHI-PROJECT-15K14412
  • [Presentation] Molecular mechanisms of the resistance to ALK- or ROS1-TKIs in ALK or ROS1 rearranged non-small cell lung cancer2015

    • Author(s)
      片山 量平
    • Organizer
      第74回 日本癌学会総会
    • Place of Presentation
      名古屋国際会議場、名古屋
    • Year and Date
      2015-10-08
    • Invited
    • Data Source
      KAKENHI-PROJECT-15K14412
  • [Presentation] Resistance mechanisms to molecular targeted therapy in ALK or ROS1 rearranged non-small cell lung cancer2015

    • Author(s)
      片山 量平
    • Organizer
      第53回 日本癌治療学会総会
    • Place of Presentation
      京都国際会議場、京都
    • Year and Date
      2015-10-29
    • Invited
    • Data Source
      KAKENHI-PROJECT-15K14412
  • [Presentation] Molecular mechanisms of the resistance to ALK- or ROS1-TKIs in ALK or ROS1 rearranged non-small cell lung cancer2015

    • Author(s)
      片山 量平
    • Organizer
      第74回 日本癌学会総会
    • Place of Presentation
      名古屋国際会議場、名古屋
    • Year and Date
      2015-10-08
    • Invited
    • Data Source
      KAKENHI-PROJECT-25710015
  • [Presentation] Resistance mechanisms to molecular targeted therapy in ALK or ROS1 rearranged non-small cell lung cancer2015

    • Author(s)
      片山 量平
    • Organizer
      第53回 日本癌治療学会総会
    • Place of Presentation
      京都国際会議場、京都
    • Year and Date
      2015-10-29
    • Invited
    • Data Source
      KAKENHI-PROJECT-25710015
  • [Presentation] Resistance mechanisms to ALK inhibitors2015

    • Author(s)
      Ryohei Katayama, Noriko Yanagitani, Sumie Koike, Takuya Sakashita, Satoru Kitazono, Makoto Nishio, Yasushi Okuno, Jeffrey A. Engelman, Alice T. Shaw, Naoya Fujita
    • Organizer
      第106回 アメリカ癌学会学術総会
    • Place of Presentation
      米国、フィラデルフィア
    • Year and Date
      2015-04-18
    • Int'l Joint Research
    • Data Source
      KAKENHI-PROJECT-25710015
  • [Presentation] Therapeutic strategies and resistance mechanisms in NTRK1 rearranged cancer2015

    • Author(s)
      布施 美保 ジェーン、藤田直也、片山量平
    • Organizer
      第74回 日本癌学会総会
    • Place of Presentation
      名古屋国際会議場、名古屋
    • Year and Date
      2015-10-08
    • Data Source
      KAKENHI-PROJECT-25710015
  • [Presentation] Novel ceritinib resistance mechanisms: new resistant mutation, fibroblast growth factor receptor 3 overexpression and cMET amplification-mediated ceritinib resistance2015

    • Author(s)
      yohei Katayama, Takuya Sakashita, Noriko Yanagitani, Kengo Takeuchi, Makoto Nishio, Naoya Fujita
    • Organizer
      AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
    • Place of Presentation
      米国、ボストン
    • Year and Date
      2015-11-05
    • Int'l Joint Research
    • Data Source
      KAKENHI-PROJECT-15K14412
  • [Presentation] ALK阻害薬耐性の分子基盤(Molecular mechanisms of ALK tyrosine kinase inhibitor resistance.)2015

    • Author(s)
      片山量平
    • Organizer
      第56回日本肺癌学会学術集会
    • Place of Presentation
      パシフィコ横浜、横浜
    • Year and Date
      2015-11-26
    • Invited
    • Data Source
      KAKENHI-PROJECT-25710015
  • [Presentation] Targeting ALK or ROS1 Positive NSCLC: Mechanisms of and Strategies to Overcome Resistance2014

    • Author(s)
      Ryohei Katayama
    • Organizer
      The 29th Nagoya International Cancer Treatment Symposium
    • Place of Presentation
      名古屋
    • Invited
    • Data Source
      KAKENHI-PROJECT-25710015
  • [Presentation] Cytotoxic Activity of Tivantinib (ARQ197) is not due solely to c-MET inhibition2013

    • Author(s)
      片山 量平、大原 智子、矢守 隆夫、 藤田 直也
    • Organizer
      第72回日本癌学会学術集会
    • Place of Presentation
      横浜
    • Data Source
      KAKENHI-PROJECT-25710015
  • [Presentation] Identification of the 2nd generation ALK inhibitor-resistance mechanism in NSCLC harboring EML4-ALK2013

    • Author(s)
      小池 清恵、片山 量平、 藤田 直也
    • Organizer
      第72回日本癌学会学術集会
    • Place of Presentation
      横浜
    • Data Source
      KAKENHI-PROJECT-25710015
  • [Presentation] Clinical activity of the ALK inhibitor LDK378 in advanced, ALK-positive NSCLC2013

    • Author(s)
      Alice T. Shaw, Ranee Mehra, Dong-Wan Kim, Enriqueta Felip, Laura Q. M. Chow, D. Ross Camidge, Daniel S. W. Tan, Johan Vansteenkiste, Sunil Sharma, Tommaso De Pas, Juergen Wolf, Ryohei Katayama, Yvonne Lau, Meredith Goldwasser, Anthony L. Boral, Jeffrey A. Engelman
    • Organizer
      2013 ASCO Annual Meeting
    • Place of Presentation
      米国、シカゴ
    • Data Source
      KAKENHI-PROJECT-25710015
  • [Presentation] Therapeutic strategies to overcome crizotinib-resistance in NSCLC harboring ALK fusion2013

    • Author(s)
      片山 量平
    • Organizer
      第11回日本臨床腫瘍学会学術集会
    • Place of Presentation
      仙台
    • Invited
    • Data Source
      KAKENHI-PROJECT-25710015
  • [Presentation] Dofequidar fumarate sensitizes Side Population cells to chemotherapeutic drugs by inhibiting ABCG2/BCRP-mediated drug export2009

    • Author(s)
      Ryohei Katayama, Yoshikazu Sugimoto, Takashi Tsuruo, Naoya Fujita
    • Organizer
      第100回アメリカ癌学会総
    • Place of Presentation
      米国デンバー
    • Year and Date
      2009-04-19
    • Data Source
      KAKENHI-PROJECT-19790241
  • [Presentation] 多剤耐性克服薬 Dofequdar とCPT-11併用によるがん幹細胞標的治療の可能性2009

    • Author(s)
      片山量平
    • Organizer
      第13回日本がん分子標的治療学会学術集会
    • Place of Presentation
      徳島
    • Year and Date
      2009-06-25
    • Data Source
      KAKENHI-PROJECT-17016012
  • [Presentation] 多剤耐性克服薬 Dofequdar はABCG2を阻害しSP細胞を抗がん剤感受性化する2009

    • Author(s)
      片山量平
    • Organizer
      第68回日本癌学会学術総会
    • Place of Presentation
      横浜
    • Year and Date
      2009-10-02
    • Data Source
      KAKENHI-PROJECT-17016012
  • [Presentation] 多剤耐性克服薬DofequdarはABCG2を阻害しSP細胞を抗がん剤感受性化する2009

    • Author(s)
      片山量平、小池清恵、佐藤重男、杉本芳一、藤田直也
    • Organizer
      第68回日本癌学会学術総会
    • Place of Presentation
      パシフィコ横浜(神奈川県)
    • Year and Date
      2009-10-02
    • Data Source
      KAKENHI-PROJECT-17016012
  • [Presentation] Side Population細胞に過剰発現するABCトランスポーターの同定とその解析2008

    • Author(s)
      片山量平, 小池清恵, 佐藤重男, 鶴尾隆,藤田直也
    • Organizer
      第8回「関東ホルモンと癌研究会」
    • Place of Presentation
      東京
    • Year and Date
      2008-01-19
    • Data Source
      KAKENHI-PROJECT-19790241
  • [Presentation] TUSC4/NPRL2, a novel PDK-1-interacting protein, inhibits PDK1 tyrosine phosphorylation and its downstream signaling2008

    • Author(s)
      片山 量平
    • Organizer
      第67回日本癌学会学術総会
    • Place of Presentation
      名古屋国際会議場
    • Year and Date
      2008-10-28
    • Data Source
      KAKENHI-PROJECT-19790241
  • [Presentation] PI3K-Akt系抑制によるFOXOを介したp15INK4b、p19INK4d発現誘導とG1 arrest2008

    • Author(s)
      片山 和浩
    • Organizer
      日本薬学会第128年会
    • Place of Presentation
      横浜
    • Year and Date
      2008-03-28
    • Data Source
      KAKENHI-PROJECT-17016012
  • [Presentation] Side Population細胞に過剰発現するABCトランスポーターの解析2007

    • Author(s)
      片山 量平
    • Organizer
      第12回 関東ホルモンと癌研究会
    • Place of Presentation
      (財)癌研究会 吉田記念講堂
    • Year and Date
      2007-01-19
    • Data Source
      KAKENHI-PROJECT-19790241
  • [Presentation] Purification and characterization of side population (SP) cells from various carcinoma cell lines2007

    • Author(s)
      片山 量平
    • Organizer
      第66回日本癌学会学術総会
    • Place of Presentation
      横浜
    • Year and Date
      2007-10-03
    • Data Source
      KAKENHI-PROJECT-17016012
  • [Presentation] Purification and characterization of side population (SP) cells from various carcinoma cell lines2007

    • Author(s)
      片山量平, 小池清恵, 鶴尾隆, 藤田直也
    • Organizer
      第66回日本癌学会学術総会
    • Place of Presentation
      横浜
    • Year and Date
      2007-10-03
    • Data Source
      KAKENHI-PROJECT-19790241
  • [Presentation] Purification and characterization of side population (SP) cells from various carcinoma cell lines2007

    • Author(s)
      片山 量平
    • Organizer
      第66回 日本癌学会学術総会
    • Place of Presentation
      パシフィコ横浜
    • Year and Date
      2007-09-28
    • Data Source
      KAKENHI-PROJECT-19790241
  • [Presentation] New mechanisms of acquired resistance to ALK inhibitors

    • Author(s)
      片山 量平
    • Organizer
      19th Japanese Foundation for Cancer Research-International Symposium on Cancer Chemotherapy (JFCR-ISCC)
    • Place of Presentation
      東京
    • Year and Date
      2014-12-10 – 2014-12-11
    • Invited
    • Data Source
      KAKENHI-PROJECT-25710015
  • [Presentation] ROS1融合遺伝子陽性肺がんにおけるクリゾチニブ耐性機構とその克服法

    • Author(s)
      小林 由佳,片山 量平,藤田直也
    • Organizer
      第73回日本癌学会学術集会
    • Place of Presentation
      横浜
    • Year and Date
      2014-09-25 – 2014-09-27
    • Data Source
      KAKENHI-PROJECT-25710015
  • [Presentation] Tivantinib (ARQ197) shows antitumor activity by reduced tubulin polymerization and overcomes tubulin binder-resistance

    • Author(s)
      青山 暁,片山 量平,藤田直也
    • Organizer
      第73回日本癌学会学術集会
    • Place of Presentation
      横浜
    • Year and Date
      2014-09-25 – 2014-09-27
    • Data Source
      KAKENHI-PROJECT-25710015
  • [Presentation] Therapeutic strategies to overcome the crizotinib resistance in ROS1-rearranged lung cancers

    • Author(s)
      Ryohai Katayama, Yuka Kobayashi, Sumie Koike, Naoya Fujita
    • Organizer
      第104回 アメリカ癌学会学術総会(AACR Annual Meeting 2014)
    • Place of Presentation
      サンディエゴ、米国
    • Year and Date
      2014-04-06 – 2014-04-09
    • Data Source
      KAKENHI-PROJECT-25710015
  • [Presentation] Acquired resistance in ALK rearranged NSCLC: Mechanisms of and strategies to overcome resistance

    • Author(s)
      片山 量平,藤田直也
    • Organizer
      第73回日本癌学会学術集会
    • Place of Presentation
      横浜
    • Year and Date
      2014-09-25 – 2014-09-27
    • Invited
    • Data Source
      KAKENHI-PROJECT-25710015
  • [Presentation] ALK陽性肺がんにおけるAlectinib獲得耐性機構の同定

    • Author(s)
      小池 清恵,片山 量平,藤田直也
    • Organizer
      第73回日本癌学会学術集会
    • Place of Presentation
      横浜
    • Year and Date
      2014-09-25 – 2014-09-27
    • Data Source
      KAKENHI-PROJECT-25710015
  • [Presentation] ALK融合遺伝子陽性肺がんにおける新規Ceritinib耐性機構の同定

    • Author(s)
      坂下 卓也,片山 量平,藤田直也
    • Organizer
      第73回日本癌学会学術集会
    • Place of Presentation
      横浜
    • Year and Date
      2014-09-25 – 2014-09-27
    • Data Source
      KAKENHI-PROJECT-25710015
  • [Presentation] Resistance Mechanisms to ALK-TKIs

    • Author(s)
      片山 量平
    • Organizer
      第12回日本臨床腫瘍学会学術集会
    • Place of Presentation
      福岡
    • Year and Date
      2014-07-17 – 2014-07-19
    • Invited
    • Data Source
      KAKENHI-PROJECT-25710015
  • []

  • 1.  NISHIO Makoto (00281593)
    # of Collaborated Projects: 3 results
    # of Collaborated Products: 8 results
  • 2.  Nagayama Satoshi (70362499)
    # of Collaborated Projects: 3 results
    # of Collaborated Products: 1 results
  • 3.  FUJITA NAOYA (20280951)
    # of Collaborated Projects: 3 results
    # of Collaborated Products: 52 results
  • 4.  TOMIDA Akihiro (40251483)
    # of Collaborated Projects: 2 results
    # of Collaborated Products: 0 results
  • 5.  YANAGITANI Noriko (60400785)
    # of Collaborated Projects: 2 results
    # of Collaborated Products: 2 results
  • 6.  HAGA Naomi (40376645)
    # of Collaborated Projects: 1 results
    # of Collaborated Products: 0 results
  • 7.  MASHIMA Tetsuo (30311228)
    # of Collaborated Projects: 1 results
    # of Collaborated Products: 0 results
  • 8.  KITAZONO Satoru (90527863)
    # of Collaborated Projects: 1 results
    # of Collaborated Products: 1 results
  • 9.  Tomonaga Takeshi (80227644)
    # of Collaborated Projects: 1 results
    # of Collaborated Products: 0 results
  • 10.  Matsusaki Michiya (00419467)
    # of Collaborated Projects: 1 results
    # of Collaborated Products: 0 results
  • 11.  Ohashi Kadoaki (60729193)
    # of Collaborated Projects: 1 results
    # of Collaborated Products: 0 results
  • 12.  鶴尾 隆 (00012667)
    # of Collaborated Projects: 1 results
    # of Collaborated Products: 6 results
  • 13.  高木 聡 (20582240)
    # of Collaborated Projects: 1 results
    # of Collaborated Products: 8 results
  • 14.  田崎 創平 (50713020)
    # of Collaborated Projects: 1 results
    # of Collaborated Products: 0 results
  • 15.  竹本 愛 (20706494)
    # of Collaborated Projects: 1 results
    # of Collaborated Products: 8 results
  • 16.  石井 秀始 (10280736)
    # of Collaborated Projects: 1 results
    # of Collaborated Products: 0 results
  • 17.  井上 正宏 (10342990)
    # of Collaborated Projects: 1 results
    # of Collaborated Products: 0 results
  • 18.  西原 広史 (50322805)
    # of Collaborated Projects: 1 results
    # of Collaborated Products: 0 results
  • 19.  木浦 勝行 (10243502)
    # of Collaborated Projects: 1 results
    # of Collaborated Products: 0 results
  • 20.  荒木 望嗣 (10452492)
    # of Collaborated Projects: 1 results
    # of Collaborated Products: 0 results
  • 21.  SAKAMOTO Hiroshi
    # of Collaborated Projects: 1 results
    # of Collaborated Products: 0 results
  • 22.  SETO yosuke
    # of Collaborated Projects: 1 results
    # of Collaborated Products: 0 results
  • 23.  UCHIBORI ken
    # of Collaborated Projects: 1 results
    # of Collaborated Products: 3 results
  • 24.  TAKEUCHI kengo
    # of Collaborated Projects: 1 results
    # of Collaborated Products: 0 results
  • 25.  OH-HARA tomoko
    # of Collaborated Projects: 1 results
    # of Collaborated Products: 8 results
  • 26.  KOIKE sumie
    # of Collaborated Projects: 1 results
    # of Collaborated Products: 6 results
  • 27.  OKADA koutaroh
    # of Collaborated Projects: 1 results
    # of Collaborated Products: 6 results
  • 28.  SHIMIZU yuki
    # of Collaborated Projects: 1 results
    # of Collaborated Products: 2 results
  • 29.  HORINAKA Mano
    # of Collaborated Projects: 0 results
    # of Collaborated Products: 1 results
  • 30.  YAMADA Tadaaki
    # of Collaborated Projects: 0 results
    # of Collaborated Products: 1 results
  • 31.  TAKEUCHI Shinji
    # of Collaborated Projects: 0 results
    # of Collaborated Products: 1 results
  • 32.  SATO Shigeo
    # of Collaborated Projects: 0 results
    # of Collaborated Products: 1 results
  • 33.  AOYAMA Aki
    # of Collaborated Projects: 0 results
    # of Collaborated Products: 1 results
  • 34.  ISHIKAWA Takeshi
    # of Collaborated Projects: 0 results
    # of Collaborated Products: 1 results
  • 35.  酒井 敏行
    # of Collaborated Projects: 0 results
    # of Collaborated Products: 1 results
  • 36.  笠原 寿郎
    # of Collaborated Projects: 0 results
    # of Collaborated Products: 1 results
  • 37.  前原 一満
    # of Collaborated Projects: 0 results
    # of Collaborated Products: 1 results
  • 38.  石川 雄一
    # of Collaborated Projects: 0 results
    # of Collaborated Products: 1 results
  • 39.  内野 順治
    # of Collaborated Projects: 0 results
    # of Collaborated Products: 1 results
  • 40.  高山 浩一
    # of Collaborated Projects: 0 results
    # of Collaborated Products: 1 results
  • 41.  矢野 聖二
    # of Collaborated Projects: 0 results
    # of Collaborated Products: 1 results
  • 42.  坂田 征士
    # of Collaborated Projects: 0 results
    # of Collaborated Products: 1 results
  • 43.  植竹 裕太
    # of Collaborated Projects: 0 results
    # of Collaborated Products: 1 results

URL: 

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi